StockData
Novo Nordisk A S logo

Novo Nordisk A S (NVO) KPIs and segments

NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Score 4/30
$39.43−1.27 (-3.12%)

Close on Nov 18, 2026Market cap $176.06BP/E 11.6Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Novo Nordisk A S · năm tài chính kết thúc December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Novo Nordisk A S: 47 chỉ số vận hành, trong đó có Total Obesity Care sales (DKKm), Total GLP-1 Diabetes sales (DKKm) và Total Diabetes Care sales (DKKm), lấy từ 100 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Total Obesity Care sales (DKKm)6
23,152.0023,343.0022,445.0021,106.0020,372.0018,424.0021,406.0018,801.0013,904.0011,035.0011,229.0012,255.00
Wegovy® (total injectable & oral obesity) sales (DKKm)4
22,702.0022,769.0021,864.0020,354.0019,528.0017,360.0019,866.0017,304.0011,659.009,377.009,614.009,648.00
Wegovy® injectable (semaglutide 2.4 mg) sales (DKKm)4
19,484.0020,513.00
Wegovy® injectable (semaglutide 2.4 mg) — Reported sales growth at CER (%)(%)
0.0%26.0%
Wegovy® injectable (semaglutide 2.4 mg) — Adjusted sales excl. 340B reversal (DKKm)2
19,484.0018,235.00
Wegovy® injectable (semaglutide 2.4 mg) — Adjusted sales growth at CER (%)(%)
1.0%12.0%
Wegovy® injectable (semaglutide 2.4 mg) — U.S. 340B rebate provision reversal (DKKm)
0.002,278.00
Wegovy® injectable (semaglutide 2.4 mg) — U.S. Operations sales (DKKm)2
9,636.0011,771.00
Wegovy® injectable (semaglutide 2.4 mg) — U.S. Operations sales growth at CER (%)(%)
-22.0%-11.0%
Wegovy® injectable (semaglutide 2.4 mg) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
9,636.009,493.00
Wegovy® injectable (semaglutide 2.4 mg) — International Operations sales (DKKm)5
9,848.008,742.00
Wegovy® injectable (semaglutide 2.4 mg) — International Operations sales growth at CER (%)(%)
46.0%62.0%
Wegovy® injectable (semaglutide 2.4 mg) — EUCAN (Europe & Canada) sales (DKKm)1
5,707.004,941.00
Wegovy® injectable (semaglutide 2.4 mg) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
63.0%86.0%
Wegovy® injectable (semaglutide 2.4 mg) — Emerging Markets sales (DKKm)1
2,217.001,732.00
Wegovy® injectable (semaglutide 2.4 mg) — Emerging Markets sales growth at CER (%)(%)
55.0%35.0%
Wegovy® injectable (semaglutide 2.4 mg) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
1,590.001,653.00
Wegovy® injectable (semaglutide 2.4 mg) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-5.0%105.0%
Wegovy® injectable (semaglutide 2.4 mg) — Region China sales (DKKm)1
334.00416.00
Wegovy® injectable (semaglutide 2.4 mg) — Region China sales growth at CER (%)(%)
106.0%-36.0%
Wegovy® pill (oral semaglutide for obesity) sales — launched Q1 2026 in U.S. (DKKm)1
3,218.002,256.00
Wegovy® pill — U.S. Operations sales (DKKm)
3,141.002,256.00
Wegovy® (total injectable & oral obesity) — U.S. Operations sales (DKKm)1
12,777.0014,027.0013,767.0012,532.0012,862.0011,854.0015,143.0012,488.009,907.008,232.008,608.009,201.00
Wegovy® (total injectable & oral obesity) — North America Operations sales [reported through FY2024] (DKKm)
15,623.0012,827.0010,098.008,233.008,608.009,201.00
Wegovy® (total injectable & oral obesity) — International Operations sales (DKKm)7
9,925.008,742.008,097.007,822.006,666.005,506.004,243.004,477.001,561.001,144.001,006.00447.00
Wegovy® (total injectable & oral obesity) — International Operations sales growth at CER (%)(%)
46.0%62.0%77.0%67.0%298.0%392.0%329.0%0.0%382.0%0.0%0.0%0.0%
Wegovy® (total injectable & oral obesity) — EUCAN (Europe & Canada) sales (DKKm)1
5,707.004,941.004,822.004,382.003,500.002,679.00
Wegovy® (total injectable & oral obesity) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
63.0%86.0%77.0%100.0%114.0%150.0%
Wegovy® (total injectable & oral obesity) — Emerging Markets sales (DKKm)1
2,294.001,732.001,983.001,495.001,334.001,288.00
Wegovy® (total injectable & oral obesity) — Emerging Markets sales growth at CER (%)(%)
55.0%35.0%192.0%-16.0%0.0%0.0%
Wegovy® (total injectable & oral obesity) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
1,590.001,653.001,446.001,837.001,676.00853.00
Wegovy® (total injectable & oral obesity) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-5.0%105.0%30.0%213.0%0.0%0.0%
Wegovy® (total injectable & oral obesity) — Region China sales (DKKm)1
334.00416.00-154.00108.00156.00686.0030.00166.000.000.000.000.00
Wegovy® (total injectable & oral obesity) — Region China sales growth at CER (%)(%)
106.0%-36.0%0.0%-27.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Wegovy® (total injectable & oral obesity) — EMEA [reported through FY2024] sales (DKKm)1
2,624.002,185.001,560.001,144.001,006.00447.00
Wegovy® (total injectable & oral obesity) — EMEA [reported through FY2024] sales growth at CER (%)(%)
159.0%389.0%382.0%0.0%0.0%0.0%
Wegovy® (total injectable & oral obesity) — Rest of World [reported through FY2024] sales (DKKm)1
1,589.002,126.001.000.000.000.00
Wegovy® (total injectable & oral obesity) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%
Saxenda® (liraglutide 3.0 mg) sales (DKKm)4
450.00574.00581.00752.00844.001,064.001,540.001,497.002,245.001,658.001,615.002,607.00
Saxenda® (liraglutide 3.0 mg) — Reported sales growth at CER (%)(%)
-48.0%-45.0%-62.0%-47.0%-61.0%-35.0%-3.0%-41.0%-19.0%-49.0%-45.0%-11.0%
Saxenda® (liraglutide 3.0 mg) — Adjusted sales excl. 340B reversal (DKKm)2
450.00421.00581.00752.00844.001,064.001,540.001,497.002,245.001,658.001,615.002,607.00
Saxenda® (liraglutide 3.0 mg) — Adjusted sales growth at CER (%)(%)
-47.0%-60.0%-62.0%-47.0%-61.0%-35.0%-3.0%-41.0%-19.0%-49.0%-45.0%-11.0%
Saxenda® (liraglutide 3.0 mg) — U.S. 340B rebate provision reversal (DKKm)
0.00153.00
Saxenda® (liraglutide 3.0 mg) — U.S. Operations sales (DKKm)3
47.00156.00-5.0090.0098.0085.00298.0089.00392.00-2.00144.00877.00
Saxenda® (liraglutide 3.0 mg) — U.S. Operations sales growth at CER (%)(%)
-43.0%-93.0%-99.0%8.0%-73.0%0.0%106.0%-90.0%-58.0%-100.0%-85.0%-31.0%
Saxenda® (liraglutide 3.0 mg) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
47.003.00-5.0090.0098.0085.00298.0089.00392.00-2.00144.00877.00
Saxenda® (liraglutide 3.0 mg) — North America Operations sales [reported through FY2024] (DKKm)
411.00225.00556.00185.00325.001,024.00
Saxenda® (liraglutide 3.0 mg) — International Operations sales (DKKm)7
403.00418.00586.00662.00746.00979.001,129.001,272.001,689.001,473.001,290.001,583.00
Saxenda® (liraglutide 3.0 mg) — International Operations sales growth at CER (%)(%)
-48.0%-57.0%-53.0%-51.0%-58.0%-40.0%-10.0%-17.0%-3.0%-18.0%-23.0%2.0%
Saxenda® (liraglutide 3.0 mg) — EUCAN (Europe & Canada) sales (DKKm)1
201.00183.00262.00301.00385.00496.00
Saxenda® (liraglutide 3.0 mg) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-48.0%-63.0%-53.0%-49.0%-50.0%-41.0%
Saxenda® (liraglutide 3.0 mg) — Emerging Markets sales (DKKm)1
180.00221.00303.00297.00266.00372.00
Saxenda® (liraglutide 3.0 mg) — Emerging Markets sales growth at CER (%)(%)
-37.0%-40.0%-39.0%-38.0%-59.0%-24.0%
Saxenda® (liraglutide 3.0 mg) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
21.0014.0022.0055.0093.0093.00
Saxenda® (liraglutide 3.0 mg) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-76.0%-84.0%-85.0%-78.0%-72.0%-66.0%
Saxenda® (liraglutide 3.0 mg) — Region China sales (DKKm)1
1.000.00-1.009.002.0018.0024.0022.0031.0025.0017.0029.00
Saxenda® (liraglutide 3.0 mg) — Region China sales growth at CER (%)(%)
-50.0%-100.0%-100.0%-64.0%-90.0%-28.0%41.0%-21.0%-34.0%-51.0%-17.0%3.0%
Saxenda® (liraglutide 3.0 mg) — EMEA [reported through FY2024] sales (DKKm)1
576.00637.00874.00833.00704.00896.00
Saxenda® (liraglutide 3.0 mg) — EMEA [reported through FY2024] sales growth at CER (%)(%)
-18.0%-27.0%-20.0%-22.0%-27.0%-9.0%
Saxenda® (liraglutide 3.0 mg) — Rest of World [reported through FY2024] sales (DKKm)1
529.00613.00784.00615.00569.00658.00
Saxenda® (liraglutide 3.0 mg) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-1.0%-3.0%33.0%-8.0%-17.0%23.0%
Total Obesity Care — Reported sales growth at CER (%)(%)
15.0%35.0%11.0%18.0%53.0%65.0%91.0%55.0%34.0%42.0%114.0%200.0%
Total Obesity Care — Adjusted sales excl. 340B reversal (DKKm)2
23,152.0020,912.0022,445.0021,106.0020,372.0018,424.0021,406.0018,801.0013,904.0011,035.0011,229.0012,255.00
Total Obesity Care — Adjusted sales growth at CER (%)(%)
16.0%22.0%11.0%18.0%53.0%65.0%91.0%55.0%34.0%42.0%114.0%200.0%
Total Obesity Care — U.S. 340B rebate provision reversal (DKKm)
0.002,431.00
Total Obesity Care — U.S. Operations sales (DKKm)3
12,824.0014,183.0013,762.0012,622.0012,960.0011,939.0015,441.0012,577.0010,299.008,230.008,752.0010,078.00
Total Obesity Care — U.S. Operations sales growth at CER (%)(%)
4.0%9.0%-4.0%6.0%32.0%40.0%75.0%26.0%25.0%44.0%155.0%320.0%
Total Obesity Care — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
12,824.0011,752.0013,762.0012,622.0012,960.0011,939.0015,441.0012,577.0010,299.008,230.008,752.0010,078.00
Total Obesity Care — North America Operations sales [reported through FY2024] (DKKm)
16,034.0013,052.0010,654.008,418.008,933.0010,225.00
Total Obesity Care — International Operations sales (DKKm)7
10,328.009,160.008,683.008,484.007,412.006,485.005,372.005,749.003,250.002,617.002,296.002,030.00
Total Obesity Care — International Operations sales growth at CER (%)(%)
37.0%44.0%50.0%41.0%115.0%137.0%139.0%189.0%58.0%35.0%35.0%30.0%
Total Obesity Care — EUCAN (Europe & Canada) sales (DKKm)1
5,908.005,124.005,084.004,683.003,885.003,175.00
Total Obesity Care — EUCAN (Europe & Canada) sales growth at CER (%)(%)
52.0%63.0%55.0%68.0%62.0%66.0%
Total Obesity Care — Emerging Markets sales (DKKm)1
2,474.001,953.002,286.001,792.001,600.001,660.00
Total Obesity Care — Emerging Markets sales growth at CER (%)(%)
45.0%18.0%98.0%-20.0%120.0%207.0%
Total Obesity Care — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
1,611.001,667.001,468.001,892.001,769.00946.00
Total Obesity Care — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-9.0%87.0%15.0%125.0%451.0%250.0%
Total Obesity Care — Region China sales (DKKm)1
335.00416.00-155.00117.00158.00704.0054.00188.0031.0025.0017.0029.00
Total Obesity Care — Region China sales growth at CER (%)(%)
104.0%-37.0%-383.0%-31.0%471.0%0.0%224.0%0.0%-34.0%-51.0%-17.0%3.0%
Total Obesity Care — EMEA [reported through FY2024] sales (DKKm)1
3,200.002,822.002,434.001,977.001,710.001,343.00
Total Obesity Care — EMEA [reported through FY2024] sales growth at CER (%)(%)
86.0%111.0%71.0%63.0%69.0%35.0%
Total Obesity Care — Rest of World [reported through FY2024] sales (DKKm)1
2,118.002,739.00785.00615.00569.00658.00
Total Obesity Care — Rest of World [reported through FY2024] sales growth at CER (%)(%)
295.0%331.0%33.0%-8.0%-17.0%23.0%
Total GLP-1 Diabetes sales (DKKm)6
36,784.0048,675.0037,527.0036,735.0038,366.0039,574.0042,173.0034,935.0037,035.0034,982.0037,761.0030,635.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) sales (DKKm)6
31,556.0043,560.0032,224.0031,293.0032,713.0033,879.0035,256.0029,482.0031,117.0029,969.0031,851.0026,139.00
Ozempic® (injectable semaglutide) sales (DKKm)4
31,375.0040,480.0031,825.0030,744.0031,799.0032,721.0033,853.0029,804.0028,875.0027,810.0030,065.0023,912.00
Ozempic® (injectable semaglutide) — Reported sales growth at CER (%)(%)
0.0%32.0%1.0%9.0%15.0%15.0%12.0%26.0%30.0%43.0%85.0%56.0%
Ozempic® (injectable semaglutide) — Adjusted sales excl. 340B reversal (DKKm)2
31,375.0027,825.0031,825.0030,744.0031,799.0032,721.0033,853.0029,804.0028,875.0027,810.0030,065.0023,912.00
Ozempic® (injectable semaglutide) — Adjusted sales growth at CER (%)(%)
5.0%-8.0%1.0%9.0%15.0%15.0%12.0%26.0%30.0%43.0%85.0%56.0%
Ozempic® (injectable semaglutide) — U.S. 340B rebate provision reversal (DKKm)
0.0012,655.00
Ozempic® (injectable semaglutide) — U.S. Operations sales (DKKm)3
20,538.0030,385.0022,354.0021,272.0021,972.0022,869.0024,735.0021,074.0019,448.0018,944.0021,807.0015,373.00
Ozempic® (injectable semaglutide) — U.S. Operations sales growth at CER (%)(%)
2.0%-14.0%-2.0%7.0%19.0%17.0%13.0%38.0%46.0%51.0%106.0%53.0%
Ozempic® (injectable semaglutide) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
20,538.0017,730.0022,354.0021,272.0021,972.0022,869.0024,735.0021,074.0019,448.0018,944.0021,807.0015,373.00
Ozempic® (injectable semaglutide) — North America Operations sales [reported through FY2024] (DKKm)
26,601.0022,841.0021,085.0020,760.0023,524.0016,814.00
Ozempic® (injectable semaglutide) — International Operations sales (DKKm)7
10,837.0010,095.009,471.009,472.009,827.009,852.007,252.006,963.007,790.007,050.006,541.007,098.00
Ozempic® (injectable semaglutide) — International Operations sales growth at CER (%)(%)
10.0%6.0%8.0%13.0%8.0%12.0%12.0%-1.0%11.0%27.0%44.0%63.0%
Ozempic® (injectable semaglutide) — EUCAN (Europe & Canada) sales (DKKm)1
7,184.006,567.006,238.005,721.005,877.004,938.00
Ozempic® (injectable semaglutide) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
22.0%35.0%12.0%28.0%28.0%2.0%
Ozempic® (injectable semaglutide) — Emerging Markets sales (DKKm)1
1,458.001,375.001,333.001,501.001,827.002,574.00
Ozempic® (injectable semaglutide) — Emerging Markets sales growth at CER (%)(%)
-22.0%-44.0%-11.0%-3.0%5.0%14.0%
Ozempic® (injectable semaglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
786.00848.00789.00724.00871.00830.00
Ozempic® (injectable semaglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-10.0%9.0%4.0%9.0%4.0%15.0%
Ozempic® (injectable semaglutide) — Region China sales (DKKm)1
1,409.001,305.001,111.001,526.001,252.001,510.001,015.001,812.001,983.00952.001,008.001,600.00
Ozempic® (injectable semaglutide) — Region China sales growth at CER (%)(%)
10.0%-8.0%18.0%-11.0%-34.0%56.0%-2.0%14.0%50.0%19.0%77.0%167.0%
Ozempic® (injectable semaglutide) — EMEA [reported through FY2024] sales (DKKm)1
4,653.003,617.003,749.003,982.003,536.003,637.00
Ozempic® (injectable semaglutide) — EMEA [reported through FY2024] sales growth at CER (%)(%)
31.0%-1.0%-2.0%19.0%26.0%37.0%
Ozempic® (injectable semaglutide) — Rest of World [reported through FY2024] sales (DKKm)1
1,584.001,534.002,058.002,116.001,997.001,861.00
Ozempic® (injectable semaglutide) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-16.0%-13.0%9.0%50.0%69.0%63.0%
Victoza® (liraglutide) sales (DKKm)4
181.003,080.00399.00549.00914.001,158.001,403.00-322.002,242.002,159.001,786.002,227.00
Victoza® (liraglutide) — Reported sales growth at CER (%)(%)
-81.0%175.0%-70.0%0.0%-57.0%-46.0%-22.0%-114.0%21.0%-22.0%-45.0%-21.0%
Victoza® (liraglutide) — Adjusted sales excl. 340B reversal (DKKm)2
181.00334.00399.00549.00914.001,158.001,403.00-322.002,242.002,159.001,786.002,227.00
Victoza® (liraglutide) — Adjusted sales growth at CER (%)(%)
-74.0%-70.0%-70.0%0.0%-57.0%-46.0%-22.0%-114.0%21.0%-22.0%-45.0%-21.0%
Victoza® (liraglutide) — U.S. 340B rebate provision reversal (DKKm)
0.002,746.00
Victoza® (liraglutide) — U.S. Operations sales (DKKm)3
-8.002,755.00-11.0050.00158.00274.00526.00-1,277.001,261.001,189.00833.001,005.00
Victoza® (liraglutide) — U.S. Operations sales growth at CER (%)(%)
0.0%-97.0%-100.0%0.0%-87.0%-78.0%-40.0%-226.0%125.0%-2.0%-53.0%-30.0%
Victoza® (liraglutide) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
-8.009.00-11.0050.00158.00274.00526.00-1,277.001,261.001,189.00833.001,005.00
Victoza® (liraglutide) — North America Operations sales [reported through FY2024] (DKKm)
553.00-1,250.001,283.001,210.00911.001,044.00
Victoza® (liraglutide) — International Operations sales (DKKm)7
189.00325.00410.00499.00756.00884.00850.00928.00959.00949.00875.001,183.00
Victoza® (liraglutide) — International Operations sales growth at CER (%)(%)
-76.0%-61.0%-52.0%-45.0%-19.0%-6.0%-1.0%-21.0%-23.0%-37.0%-37.0%-11.0%
Victoza® (liraglutide) — EUCAN (Europe & Canada) sales (DKKm)1
54.0071.00127.00121.00195.00251.00
Victoza® (liraglutide) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-72.0%-71.0%-54.0%-64.0%-34.0%-1.0%
Victoza® (liraglutide) — Emerging Markets sales (DKKm)1
24.00104.00124.00189.00392.00345.00
Victoza® (liraglutide) — Emerging Markets sales growth at CER (%)(%)
-95.0%-67.0%-66.0%-46.0%29.0%75.0%
Victoza® (liraglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
12.0023.0043.0048.0059.0054.00
Victoza® (liraglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-78.0%-52.0%-39.0%-35.0%-47.0%-50.0%
Victoza® (liraglutide) — Region China sales (DKKm)1
99.00127.00116.00141.00110.00234.00164.00170.00245.00396.00226.00192.00
Victoza® (liraglutide) — Region China sales growth at CER (%)(%)
-15.0%-43.0%-24.0%-12.0%-51.0%-42.0%-30.0%-14.0%-34.0%-9.0%-35.0%-39.0%
Victoza® (liraglutide) — EMEA [reported through FY2024] sales (DKKm)1
327.00361.00397.00337.00274.00612.00
Victoza® (liraglutide) — EMEA [reported through FY2024] sales growth at CER (%)(%)
20.0%-41.0%-28.0%-54.0%-56.0%-4.0%
Victoza® (liraglutide) — Rest of World [reported through FY2024] sales (DKKm)1
359.00397.00317.00216.00375.00379.00
Victoza® (liraglutide) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
0.0%7.0%1.0%-37.0%-10.0%7.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Reported sales growth at CER (%)(%)
-2.0%37.0%-2.0%12.0%10.0%11.0%10.0%14.0%29.0%35.0%64.0%44.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Adjusted sales excl. 340B reversal (DKKm)2
31,556.0028,159.0032,224.0031,293.0032,713.0033,879.0035,256.0029,482.0031,117.0029,969.0031,851.0026,139.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Adjusted sales growth at CER (%)(%)
3.0%-10.0%-2.0%12.0%10.0%11.0%10.0%14.0%29.0%35.0%64.0%44.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — U.S. 340B rebate provision reversal (DKKm)
0.0015,401.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — U.S. Operations sales (DKKm)3
20,530.0033,140.0022,343.0021,322.0022,130.0023,143.0025,261.0019,797.0020,709.0020,133.0022,640.0016,378.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — U.S. Operations sales growth at CER (%)(%)
3.0%-15.0%-4.0%14.0%12.0%11.0%11.0%22.0%49.0%47.0%83.0%43.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
20,530.0017,739.0022,343.0021,322.0022,130.0023,143.0025,261.0019,797.0020,709.0020,133.0022,640.0016,378.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — North America Operations sales [reported through FY2024] (DKKm)
27,154.0021,591.0022,368.0021,970.0024,435.0017,858.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — International Operations sales (DKKm)7
11,026.0010,420.009,881.009,971.0010,583.0010,736.008,102.007,891.008,749.007,999.007,416.008,281.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — International Operations sales growth at CER (%)(%)
4.0%0.0%3.0%7.0%6.0%10.0%10.0%-4.0%6.0%13.0%26.0%46.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — EUCAN (Europe & Canada) sales (DKKm)1
7,238.006,638.006,365.005,842.006,072.005,189.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
19.0%30.0%9.0%22.0%25.0%2.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Emerging Markets sales (DKKm)1
1,482.001,479.001,457.001,690.002,219.002,919.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Emerging Markets sales growth at CER (%)(%)
-35.0%-46.0%-21.0%-11.0%8.0%19.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
798.00871.00832.00772.00930.00884.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-14.0%5.0%0.0%4.0%-2.0%7.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Region China sales (DKKm)1
1,508.001,432.001,227.001,667.001,362.001,744.001,179.001,982.002,228.001,348.001,234.001,792.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Region China sales growth at CER (%)(%)
8.0%-13.0%12.0%-11.0%-35.0%27.0%-7.0%11.0%32.0%9.0%35.0%93.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — EMEA [reported through FY2024] sales (DKKm)1
4,980.003,978.004,146.004,319.003,810.004,249.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — EMEA [reported through FY2024] sales growth at CER (%)(%)
31.0%-6.0%-5.0%6.0%11.0%29.0%
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Rest of World [reported through FY2024] sales (DKKm)1
1,943.001,931.002,375.002,332.002,372.002,240.00
Injectable GLP-1 diabetes (Ozempic® + Victoza®) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-13.0%-10.0%8.0%33.0%50.0%51.0%
Rybelsus® / Ozempic® pill (oral semaglutide) sales (DKKm)4
5,228.005,115.005,303.005,442.005,653.005,695.006,917.005,453.005,918.005,013.005,910.004,496.00
Rybelsus® / Ozempic® pill (oral semaglutide) — Reported sales growth at CER (%)(%)
-5.0%-5.0%-19.0%4.0%-1.0%13.0%18.0%23.0%49.0%17.0%51.0%59.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — Adjusted sales excl. 340B reversal (DKKm)2
5,228.004,572.005,303.005,442.005,653.005,695.006,917.005,453.005,918.005,013.005,910.004,496.00
Rybelsus® / Ozempic® pill (oral semaglutide) — Adjusted sales growth at CER (%)(%)
-4.0%-15.0%-19.0%4.0%-1.0%13.0%18.0%23.0%49.0%17.0%51.0%59.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — U.S. 340B rebate provision reversal (DKKm)
0.00543.00
Rybelsus® / Ozempic® pill (oral semaglutide) — U.S. Operations sales (DKKm)3
2,273.002,127.002,176.001,986.002,262.002,409.003,116.002,434.002,909.002,336.003,666.002,545.00
Rybelsus® / Ozempic® pill (oral semaglutide) — U.S. Operations sales growth at CER (%)(%)
7.0%-27.0%-24.0%-13.0%-18.0%0.0%-16.0%-3.0%32.0%-11.0%35.0%29.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
2,273.001,584.002,176.001,986.002,262.002,409.003,116.002,434.002,909.002,336.003,666.002,545.00
Rybelsus® / Ozempic® pill (oral semaglutide) — North America Operations sales [reported through FY2024] (DKKm)
3,192.002,509.002,976.002,393.003,824.002,604.00
Rybelsus® / Ozempic® pill (oral semaglutide) — International Operations sales (DKKm)7
2,955.002,988.003,127.003,456.003,391.003,286.003,725.002,944.002,942.002,620.002,086.001,892.00
Rybelsus® / Ozempic® pill (oral semaglutide) — International Operations sales growth at CER (%)(%)
-12.0%-6.0%-15.0%18.0%15.0%25.0%82.0%60.0%72.0%61.0%81.0%131.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — EUCAN (Europe & Canada) sales (DKKm)1
1,454.001,538.001,645.001,686.001,853.001,881.00
Rybelsus® / Ozempic® pill (oral semaglutide) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-22.0%-18.0%-19.0%-1.0%12.0%36.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — Emerging Markets sales (DKKm)1
765.00589.00556.00439.00539.00527.00
Rybelsus® / Ozempic® pill (oral semaglutide) — Emerging Markets sales growth at CER (%)(%)
33.0%10.0%-1.0%-8.0%16.0%1.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
761.00835.00857.00896.00940.00821.00
Rybelsus® / Ozempic® pill (oral semaglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-10.0%15.0%12.0%23.0%21.0%23.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — Region China sales (DKKm)1
-25.0026.0069.00435.0059.0057.00360.0043.0053.0055.0035.0029.00
Rybelsus® / Ozempic® pill (oral semaglutide) — Region China sales growth at CER (%)(%)
-120.0%-33.0%-80.0%0.0%9.0%5.0%0.0%55.0%77.0%58.0%52.0%120.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — EMEA [reported through FY2024] sales (DKKm)1
2,025.001,786.001,702.001,623.001,196.001,063.00
Rybelsus® / Ozempic® pill (oral semaglutide) — EMEA [reported through FY2024] sales growth at CER (%)(%)
69.0%69.0%70.0%67.0%70.0%137.0%
Rybelsus® / Ozempic® pill (oral semaglutide) — Rest of World [reported through FY2024] sales (DKKm)1
1,340.001,115.001,187.00942.00855.00800.00
Rybelsus® / Ozempic® pill (oral semaglutide) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
65.0%48.0%74.0%53.0%101.0%124.0%
Total GLP-1 Diabetes — Reported sales growth at CER (%)(%)
-2.0%31.0%-5.0%11.0%8.0%11.0%12.0%15.0%32.0%32.0%62.0%46.0%
Total GLP-1 Diabetes — Adjusted sales excl. 340B reversal (DKKm)2
36,784.0032,731.0037,527.0036,735.0038,366.0039,574.0042,173.0034,935.0037,035.0034,982.0037,761.0030,635.00
Total GLP-1 Diabetes — Adjusted sales growth at CER (%)(%)
2.0%-11.0%-5.0%11.0%8.0%11.0%12.0%15.0%32.0%32.0%62.0%46.0%
Total GLP-1 Diabetes — U.S. 340B rebate provision reversal (DKKm)
0.0015,944.00
Total GLP-1 Diabetes — U.S. Operations sales (DKKm)3
22,803.0035,267.0024,519.0023,308.0024,392.0025,552.0028,377.0022,231.0023,618.0022,469.0026,306.0018,923.00
Total GLP-1 Diabetes — U.S. Operations sales growth at CER (%)(%)
3.0%-16.0%-6.0%11.0%9.0%10.0%7.0%19.0%46.0%37.0%74.0%41.0%
Total GLP-1 Diabetes — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
22,803.0019,323.0024,519.0023,308.0024,392.0025,552.0028,377.0022,231.0023,618.0022,469.0026,306.0018,923.00
Total GLP-1 Diabetes — North America Operations sales [reported through FY2024] (DKKm)
30,346.0024,100.0025,344.0024,363.0028,259.0020,462.00
Total GLP-1 Diabetes — International Operations sales (DKKm)7
13,981.0013,408.0013,008.0013,427.0013,974.0014,022.0011,827.0010,835.0011,691.0010,619.009,502.0010,173.00
Total GLP-1 Diabetes — International Operations sales growth at CER (%)(%)
0.0%-1.0%-2.0%9.0%8.0%13.0%26.0%8.0%18.0%22.0%35.0%57.0%
Total GLP-1 Diabetes — EUCAN (Europe & Canada) sales (DKKm)1
8,692.008,176.008,010.007,528.007,925.007,070.00
Total GLP-1 Diabetes — EUCAN (Europe & Canada) sales growth at CER (%)(%)
10.0%17.0%2.0%16.0%22.0%9.0%
Total GLP-1 Diabetes — Emerging Markets sales (DKKm)1
2,247.002,068.002,013.002,129.002,758.003,446.00
Total GLP-1 Diabetes — Emerging Markets sales growth at CER (%)(%)
-22.0%-38.0%-16.0%-10.0%10.0%16.0%
Total GLP-1 Diabetes — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
1,559.001,706.001,689.001,668.001,870.001,705.00
Total GLP-1 Diabetes — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-12.0%10.0%6.0%13.0%8.0%14.0%
Total GLP-1 Diabetes — Region China sales (DKKm)1
1,483.001,458.001,296.002,102.001,421.001,801.001,539.002,025.002,281.001,403.001,269.001,821.00
Total GLP-1 Diabetes — Region China sales growth at CER (%)(%)
3.0%-14.0%-9.0%9.0%-34.0%26.0%19.0%11.0%33.0%10.0%35.0%93.0%
Total GLP-1 Diabetes — EMEA [reported through FY2024] sales (DKKm)1
7,005.005,764.005,848.005,942.005,006.005,312.00
Total GLP-1 Diabetes — EMEA [reported through FY2024] sales growth at CER (%)(%)
40.0%9.0%9.0%18.0%21.0%42.0%
Total GLP-1 Diabetes — Rest of World [reported through FY2024] sales (DKKm)1
3,283.003,046.003,562.003,274.003,227.003,040.00
Total GLP-1 Diabetes — Rest of World [reported through FY2024] sales growth at CER (%)(%)
7.0%5.0%24.0%38.0%61.0%65.0%
Total Diabetes Care sales (DKKm)6
50,429.0068,019.0051,350.0049,149.0051,566.0055,044.0058,572.0047,936.0050,180.0049,930.0050,063.0042,574.00
Total Insulin sales (DKKm)8
12,941.0018,784.0013,401.0011,993.0012,746.0014,997.0015,887.0012,509.0012,612.0014,365.0011,980.0011,345.00
Long-acting insulin sales (DKKm)8
4,412.008,112.004,700.004,200.004,467.005,388.005,158.004,035.004,737.005,165.003,726.003,692.00
Tresiba® (insulin degludec) sales (DKKm)3
3,048.002,624.002,800.003,577.002,735.002,110.002,297.002,763.001,916.001,910.00
Tresiba® (insulin degludec) — Reported sales growth at CER (%)(%)
18.0%31.0%27.0%27.0%45.0%11.0%31.0%30.0%-12.0%-10.0%
Tresiba® (insulin degludec) — U.S. Operations sales (DKKm)2
1,241.00790.00975.001,700.00952.00383.00547.00924.00278.00290.00
Tresiba® (insulin degludec) — U.S. Operations sales growth at CER (%)(%)
41.0%124.0%93.0%78.0%241.0%34.0%131.0%75.0%-53.0%-50.0%
Tresiba® (insulin degludec) — North America Operations sales [reported through FY2024] (DKKm)
1,107.00535.00700.001,069.00424.00429.00
Tresiba® (insulin degludec) — International Operations sales (DKKm)7
1,807.001,834.001,825.001,877.001,628.001,575.001,597.001,694.001,492.001,481.00
Tresiba® (insulin degludec) — International Operations sales growth at CER (%)(%)
6.0%11.0%7.0%2.0%12.0%6.0%17.0%16.0%4.0%4.0%
Tresiba® (insulin degludec) — EUCAN (Europe & Canada) sales (DKKm)1
906.00899.00899.00863.00
Tresiba® (insulin degludec) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-4.0%2.0%-2.0%1.0%
Tresiba® (insulin degludec) — Emerging Markets sales (DKKm)1
477.00497.00486.00520.00
Tresiba® (insulin degludec) — Emerging Markets sales growth at CER (%)(%)
40.0%36.0%25.0%6.0%
Tresiba® (insulin degludec) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
213.00201.00215.00218.00
Tresiba® (insulin degludec) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
12.0%6.0%9.0%-3.0%
Tresiba® (insulin degludec) — Region China sales (DKKm)1
211.00237.00225.00276.00253.00235.00218.00272.00207.00205.00
Tresiba® (insulin degludec) — Region China sales growth at CER (%)(%)
-10.0%6.0%9.0%0.0%21.0%15.0%13.0%20.0%8.0%-20.0%
Tresiba® (insulin degludec) — EMEA [reported through FY2024] sales (DKKm)1
976.00930.00979.00991.00846.00915.00
Tresiba® (insulin degludec) — EMEA [reported through FY2024] sales growth at CER (%)(%)
18.0%3.0%24.0%15.0%0.0%19.0%
Tresiba® (insulin degludec) — Rest of World [reported through FY2024] sales (DKKm)1
399.00410.00400.00431.00439.00361.00
Tresiba® (insulin degludec) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-3.0%11.0%4.0%16.0%12.0%-9.0%
Xultophy® (insulin degludec / liraglutide) sales (DKKm)3
1,158.001,120.001,132.001,209.001,274.001,039.001,067.001,123.00786.00798.00
Xultophy® (insulin degludec / liraglutide) — Reported sales growth at CER (%)(%)
-5.0%12.0%10.0%7.0%64.0%32.0%27.0%48.0%15.0%18.0%
Xultophy® (insulin degludec / liraglutide) — U.S. Operations sales (DKKm)2
93.0056.0057.0089.0076.0057.0054.0094.0065.0091.00
Xultophy® (insulin degludec / liraglutide) — U.S. Operations sales growth at CER (%)(%)
33.0%5.0%13.0%-9.0%16.0%-36.0%-28.0%-1.0%-22.0%11.0%
Xultophy® (insulin degludec / liraglutide) — North America Operations sales [reported through FY2024] (DKKm)
77.0059.0054.0096.0067.0092.00
Xultophy® (insulin degludec / liraglutide) — International Operations sales (DKKm)7
1,065.001,064.001,075.001,120.001,197.00980.001,013.001,027.00719.00706.00
Xultophy® (insulin degludec / liraglutide) — International Operations sales growth at CER (%)(%)
-8.0%12.0%10.0%9.0%68.0%41.0%32.0%55.0%21.0%20.0%
Xultophy® (insulin degludec / liraglutide) — EUCAN (Europe & Canada) sales (DKKm)1
468.00444.00470.00482.00
Xultophy® (insulin degludec / liraglutide) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-16.0%-14.0%-7.0%-1.0%
Xultophy® (insulin degludec / liraglutide) — Emerging Markets sales (DKKm)1
69.0077.0076.0088.00
Xultophy® (insulin degludec / liraglutide) — Emerging Markets sales growth at CER (%)(%)
-30.0%25.0%10.0%-13.0%
Xultophy® (insulin degludec / liraglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
85.0089.0095.0089.00
Xultophy® (insulin degludec / liraglutide) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-9.0%7.0%2.0%-16.0%
Xultophy® (insulin degludec / liraglutide) — Region China sales (DKKm)1
443.00454.00434.00461.00444.00313.00334.00323.0091.00144.00
Xultophy® (insulin degludec / liraglutide) — Region China sales growth at CER (%)(%)
7.0%54.0%36.0%40.0%386.0%117.0%167.0%0.0%0.0%0.0%
Xultophy® (insulin degludec / liraglutide) — EMEA [reported through FY2024] sales (DKKm)1
584.00537.00523.00541.00477.00431.00
Xultophy® (insulin degludec / liraglutide) — EMEA [reported through FY2024] sales growth at CER (%)(%)
24.0%26.0%15.0%18.0%12.0%2.0%
Xultophy® (insulin degludec / liraglutide) — Rest of World [reported through FY2024] sales (DKKm)1
169.00130.00156.00163.00151.00131.00
Xultophy® (insulin degludec / liraglutide) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
17.0%6.0%-15.0%-1.0%-7.0%-20.0%
Levemir® (insulin detemir) sales (DKKm)3
345.00314.00475.00543.001,139.00879.001,371.001,279.001,024.00984.00
Levemir® (insulin detemir) — Reported sales growth at CER (%)(%)
-69.0%-63.0%-65.0%-58.0%11.0%-11.0%82.0%12.0%15.0%12.0%
Levemir® (insulin detemir) — U.S. Operations sales (DKKm)2
-28.00-20.0054.000.00615.00404.00783.00649.00430.00416.00
Levemir® (insulin detemir) — U.S. Operations sales growth at CER (%)(%)
-105.0%-105.0%-93.0%-100.0%42.0%-2.0%0.0%77.0%39.0%21.0%
Levemir® (insulin detemir) — North America Operations sales [reported through FY2024] (DKKm)
627.00417.00800.00666.00448.00429.00
Levemir® (insulin detemir) — International Operations sales (DKKm)7
373.00334.00421.00543.00512.00462.00571.00613.00576.00555.00
Levemir® (insulin detemir) — International Operations sales growth at CER (%)(%)
-27.0%-27.0%-27.0%-15.0%-11.0%-19.0%-15.0%-18.0%4.0%8.0%
Levemir® (insulin detemir) — EUCAN (Europe & Canada) sales (DKKm)1
148.00164.00203.00202.00
Levemir® (insulin detemir) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-39.0%-25.0%-23.0%-20.0%
Levemir® (insulin detemir) — Emerging Markets sales (DKKm)1
152.00114.00160.00257.00
Levemir® (insulin detemir) — Emerging Markets sales growth at CER (%)(%)
-15.0%-32.0%-25.0%6.0%
Levemir® (insulin detemir) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
22.0022.0020.0030.00
Levemir® (insulin detemir) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-26.0%-4.0%-36.0%3.0%
Levemir® (insulin detemir) — Region China sales (DKKm)1
51.0034.0038.0054.0064.0052.0072.00110.0080.0088.00
Levemir® (insulin detemir) — Region China sales growth at CER (%)(%)
-16.0%-29.0%-44.0%-52.0%-21.0%-43.0%-24.0%-9.0%-8.0%51.0%
Levemir® (insulin detemir) — EMEA [reported through FY2024] sales (DKKm)1
390.00354.00440.00432.00406.00384.00
Levemir® (insulin detemir) — EMEA [reported through FY2024] sales growth at CER (%)(%)
-4.0%-10.0%-10.0%-18.0%-2.0%13.0%
Levemir® (insulin detemir) — Rest of World [reported through FY2024] sales (DKKm)1
58.0056.0059.0071.0090.0083.00
Levemir® (insulin detemir) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-36.0%-34.0%-31.0%-28.0%51.0%-29.0%
Awiqli® (once-weekly insulin icodec) sales (DKKm)3
149.00142.0060.0059.0010.007.002.00
Awiqli® (once-weekly insulin icodec) — Reported sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — U.S. Operations sales (DKKm)2
0.000.000.000.000.000.000.00
Awiqli® (once-weekly insulin icodec) — U.S. Operations sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — North America Operations sales [reported through FY2024] (DKKm)
2.000.002.00
Awiqli® (once-weekly insulin icodec) — International Operations sales (DKKm)7
149.00142.0060.0059.008.007.000.00
Awiqli® (once-weekly insulin icodec) — International Operations sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — EUCAN (Europe & Canada) sales (DKKm)1
41.0028.0022.0013.00
Awiqli® (once-weekly insulin icodec) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
0.0%314.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — Emerging Markets sales (DKKm)1
0.000.000.000.00
Awiqli® (once-weekly insulin icodec) — Emerging Markets sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
9.004.003.002.00
Awiqli® (once-weekly insulin icodec) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — Region China sales (DKKm)1
99.00110.0035.0044.006.000.000.00
Awiqli® (once-weekly insulin icodec) — Region China sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — EMEA [reported through FY2024] sales (DKKm)1
2.007.000.00
Awiqli® (once-weekly insulin icodec) — EMEA [reported through FY2024] sales growth at CER (%)(%)
0.0%0.0%0.0%
Awiqli® (once-weekly insulin icodec) — Rest of World [reported through FY2024] sales (DKKm)1
0.000.000.00
Awiqli® (once-weekly insulin icodec) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
0.0%0.0%0.0%
Long-acting insulin — Reported sales growth at CER (%)(%)
-1.0%57.0%-4.0%9.0%-2.0%3.0%40.0%10.0%42.0%28.0%0.0%0.0%
Long-acting insulin — Adjusted sales excl. 340B reversal (DKKm)2
4,412.004,232.004,700.004,200.004,467.005,388.005,158.004,035.004,737.005,165.003,726.003,692.00
Long-acting insulin — Adjusted sales growth at CER (%)(%)
8.0%-17.0%-4.0%9.0%-2.0%3.0%40.0%10.0%42.0%28.0%0.0%0.0%
Long-acting insulin — U.S. 340B rebate provision reversal (DKKm)
0.003,880.00
Long-acting insulin — U.S. Operations sales (DKKm)3
749.004,743.001,306.00826.001,086.001,789.001,643.00844.001,384.001,667.00773.00797.00
Long-acting insulin — U.S. Operations sales growth at CER (%)(%)
9.0%-46.0%-14.0%6.0%-16.0%4.0%111.0%7.0%277.0%69.0%-22.0%-21.0%
Long-acting insulin — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
749.00863.001,306.00826.001,086.001,789.001,643.00844.001,384.001,667.00773.00797.00
Long-acting insulin — North America Operations sales [reported through FY2024] (DKKm)
1,813.001,011.001,556.001,831.00939.00950.00
Long-acting insulin — International Operations sales (DKKm)7
3,663.003,369.003,394.003,374.003,381.003,599.003,345.003,024.003,181.003,334.002,787.002,742.00
Long-acting insulin — International Operations sales growth at CER (%)(%)
8.0%-3.0%0.0%10.0%4.0%3.0%22.0%10.0%14.0%16.0%8.0%9.0%
Long-acting insulin — EUCAN (Europe & Canada) sales (DKKm)1
1,527.001,544.001,563.001,535.001,594.001,560.00
Long-acting insulin — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-4.0%0.0%-10.0%-5.0%-5.0%-2.0%
Long-acting insulin — Emerging Markets sales (DKKm)1
854.00700.00698.00688.00722.00865.00
Long-acting insulin — Emerging Markets sales growth at CER (%)(%)
17.0%-15.0%14.0%16.0%8.0%4.0%
Long-acting insulin — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
286.00260.00329.00316.00333.00339.00
Long-acting insulin — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-4.0%-13.0%5.0%6.0%4.0%-6.0%
Long-acting insulin — Region China sales (DKKm)1
996.00865.00804.00835.00732.00835.00767.00600.00624.00705.00378.00437.00
Long-acting insulin — Region China sales growth at CER (%)(%)
33.0%10.0%12.0%47.0%23.0%16.0%102.0%37.0%51.0%80.0%31.0%34.0%
Long-acting insulin — EMEA [reported through FY2024] sales (DKKm)1
1,952.001,828.001,942.001,964.001,729.001,730.00
Long-acting insulin — EMEA [reported through FY2024] sales growth at CER (%)(%)
15.0%6.0%12.0%6.0%3.0%13.0%
Long-acting insulin — Rest of World [reported through FY2024] sales (DKKm)1
626.00596.00615.00665.00680.00575.00
Long-acting insulin — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-3.0%4.0%-6.0%5.0%12.0%-16.0%
Premix insulin sales (DKKm)6
2,790.002,636.002,509.002,357.002,636.002,813.002,867.002,518.002,436.002,968.002,123.002,219.00
Ryzodeg® (insulin degludec / insulin aspart) sales (DKKm)3
1,298.001,289.001,363.001,432.001,346.001,153.001,163.001,267.00909.00864.00
Ryzodeg® (insulin degludec / insulin aspart) — Reported sales growth at CER (%)(%)
4.0%18.0%20.0%12.0%48.0%35.0%21.0%38.0%42.0%22.0%
Ryzodeg® (insulin degludec / insulin aspart) — U.S. Operations sales (DKKm)2
0.000.000.000.000.000.000.000.000.000.00
Ryzodeg® (insulin degludec / insulin aspart) — U.S. Operations sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Ryzodeg® (insulin degludec / insulin aspart) — North America Operations sales [reported through FY2024] (DKKm)
0.000.000.000.000.000.00
Ryzodeg® (insulin degludec / insulin aspart) — International Operations sales (DKKm)7
1,298.001,289.001,363.001,432.001,346.001,153.001,163.001,267.00909.00864.00
Ryzodeg® (insulin degludec / insulin aspart) — International Operations sales growth at CER (%)(%)
4.0%18.0%20.0%12.0%48.0%35.0%21.0%38.0%42.0%22.0%
Ryzodeg® (insulin degludec / insulin aspart) — EUCAN (Europe & Canada) sales (DKKm)1
58.0055.0055.0057.00
Ryzodeg® (insulin degludec / insulin aspart) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
10.0%23.0%24.0%24.0%
Ryzodeg® (insulin degludec / insulin aspart) — Emerging Markets sales (DKKm)1
199.00194.00265.00219.00
Ryzodeg® (insulin degludec / insulin aspart) — Emerging Markets sales growth at CER (%)(%)
42.0%34.0%55.0%31.0%
Ryzodeg® (insulin degludec / insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
339.00333.00345.00299.00
Ryzodeg® (insulin degludec / insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
0.0%15.0%18.0%-10.0%
Ryzodeg® (insulin degludec / insulin aspart) — Region China sales (DKKm)1
702.00707.00698.00857.00764.00642.00655.00721.00450.00482.00
Ryzodeg® (insulin degludec / insulin aspart) — Region China sales growth at CER (%)(%)
-1.0%16.0%12.0%17.0%68.0%33.0%25.0%53.0%48.0%44.0%
Ryzodeg® (insulin degludec / insulin aspart) — EMEA [reported through FY2024] sales (DKKm)1
162.00167.00181.00191.00132.00129.00
Ryzodeg® (insulin degludec / insulin aspart) — EMEA [reported through FY2024] sales growth at CER (%)(%)
22.0%33.0%10.0%28.0%30.0%11.0%
Ryzodeg® (insulin degludec / insulin aspart) — Rest of World [reported through FY2024] sales (DKKm)1
420.00344.00327.00355.00327.00253.00
Ryzodeg® (insulin degludec / insulin aspart) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
29.0%39.0%19.0%18.0%39.0%-2.0%
NovoMix® (biphasic insulin aspart) sales (DKKm)3
1,211.001,068.001,273.001,381.001,521.001,365.001,273.001,701.001,214.001,355.00
NovoMix® (biphasic insulin aspart) — Reported sales growth at CER (%)(%)
-15.0%-17.0%2.0%-21.0%23.0%0.0%-14.0%-3.0%-4.0%-20.0%
NovoMix® (biphasic insulin aspart) — U.S. Operations sales (DKKm)2
151.00149.00130.00137.00278.0095.0063.00196.00-51.004.00
NovoMix® (biphasic insulin aspart) — U.S. Operations sales growth at CER (%)(%)
-41.0%64.0%119.0%-33.0%0.0%0.0%-53.0%47.0%-130.0%-86.0%
NovoMix® (biphasic insulin aspart) — North America Operations sales [reported through FY2024] (DKKm)
281.0099.0067.00199.00-47.008.00
NovoMix® (biphasic insulin aspart) — International Operations sales (DKKm)7
1,060.00919.001,143.001,244.001,240.001,266.001,206.001,502.001,261.001,347.00
NovoMix® (biphasic insulin aspart) — International Operations sales growth at CER (%)(%)
-10.0%-23.0%-4.0%-20.0%-4.0%-7.0%-10.0%-7.0%11.0%-17.0%
NovoMix® (biphasic insulin aspart) — EUCAN (Europe & Canada) sales (DKKm)1
178.00161.00183.00183.00
NovoMix® (biphasic insulin aspart) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-16.0%-20.0%-16.0%-17.0%
NovoMix® (biphasic insulin aspart) — Emerging Markets sales (DKKm)1
315.00190.00343.00324.00
NovoMix® (biphasic insulin aspart) — Emerging Markets sales growth at CER (%)(%)
-21.0%-46.0%15.0%-17.0%
NovoMix® (biphasic insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
197.00209.00189.00195.00
NovoMix® (biphasic insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-13.0%2.0%-13.0%-18.0%
NovoMix® (biphasic insulin aspart) — Region China sales (DKKm)1
370.00359.00428.00542.00366.00467.00484.00685.00503.00579.00
NovoMix® (biphasic insulin aspart) — Region China sales growth at CER (%)(%)
9.0%-18.0%-7.0%-22.0%-29.0%-20.0%-16.0%-10.0%-20.0%-29.0%
NovoMix® (biphasic insulin aspart) — EMEA [reported through FY2024] sales (DKKm)1
511.00493.00436.00496.00473.00479.00
NovoMix® (biphasic insulin aspart) — EMEA [reported through FY2024] sales growth at CER (%)(%)
6.0%2.0%-11.0%-9.0%-8.0%-1.0%
NovoMix® (biphasic insulin aspart) — Rest of World [reported through FY2024] sales (DKKm)1
363.00306.00286.00321.00285.00289.00
NovoMix® (biphasic insulin aspart) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
25.0%3.0%6.0%7.0%137.0%-10.0%
Premix insulin — Reported sales growth at CER (%)(%)
0.0%0.0%-6.0%-1.0%11.0%-7.0%33.0%13.0%0.0%12.0%10.0%-8.0%
Premix insulin — Adjusted sales excl. 340B reversal (DKKm)2
2,790.002,395.002,509.002,357.002,636.002,813.002,867.002,518.002,436.002,968.002,123.002,219.00
Premix insulin — Adjusted sales growth at CER (%)(%)
1.0%-9.0%-6.0%-1.0%11.0%-7.0%33.0%13.0%0.0%12.0%10.0%-8.0%
Premix insulin — U.S. 340B rebate provision reversal (DKKm)
0.00241.00
Premix insulin — U.S. Operations sales (DKKm)3
118.00322.00151.00149.00130.00137.00278.0095.0063.00196.00-51.004.00
Premix insulin — U.S. Operations sales growth at CER (%)(%)
13.0%-34.0%-41.0%64.0%119.0%-33.0%0.0%0.0%-53.0%47.0%-130.0%-86.0%
Premix insulin — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
118.0081.00151.00149.00130.00137.00278.0095.0063.00196.00-51.004.00
Premix insulin — North America Operations sales [reported through FY2024] (DKKm)
281.0099.0067.00199.00-47.008.00
Premix insulin — International Operations sales (DKKm)7
2,672.002,314.002,358.002,208.002,506.002,676.002,586.002,419.002,369.002,769.002,170.002,211.00
Premix insulin — International Operations sales growth at CER (%)(%)
0.0%-7.0%-2.0%-3.0%8.0%-5.0%18.0%9.0%3.0%10.0%21.0%-5.0%
Premix insulin — EUCAN (Europe & Canada) sales (DKKm)1
208.00215.00236.00216.00238.00240.00
Premix insulin — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-12.0%-10.0%-11.0%-13.0%-9.0%-10.0%
Premix insulin — Emerging Markets sales (DKKm)1
777.00431.00514.00384.00608.00543.00
Premix insulin — Emerging Markets sales growth at CER (%)(%)
1.0%-14.0%-4.0%-23.0%29.0%-2.0%
Premix insulin — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
490.00528.00536.00542.00534.00494.00
Premix insulin — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-1.0%20.0%-5.0%10.0%5.0%-14.0%
Premix insulin — Region China sales (DKKm)1
1,197.001,140.001,072.001,066.001,126.001,399.001,130.001,109.001,139.001,406.00953.001,061.00
Premix insulin — Region China sales growth at CER (%)(%)
3.0%-14.0%2.0%2.0%4.0%-2.0%17.0%4.0%3.0%14.0%2.0%-7.0%
Premix insulin — EMEA [reported through FY2024] sales (DKKm)1
673.00660.00617.00687.00605.00608.00
Premix insulin — EMEA [reported through FY2024] sales growth at CER (%)(%)
10.0%9.0%-5.0%0.0%-1.0%1.0%
Premix insulin — Rest of World [reported through FY2024] sales (DKKm)1
783.00650.00613.00676.00612.00542.00
Premix insulin — Rest of World [reported through FY2024] sales growth at CER (%)(%)
27.0%20.0%13.0%13.0%83.0%-6.0%
Fast-acting insulin sales (DKKm)6
4,691.006,879.004,880.004,109.004,542.005,052.006,017.004,150.003,868.004,487.004,142.003,808.00
NovoRapid® / NovoLog® (insulin aspart) sales (DKKm)3
4,043.003,477.004,027.004,218.005,674.003,756.003,303.003,920.003,508.003,234.00
NovoRapid® / NovoLog® (insulin aspart) — Reported sales growth at CER (%)(%)
-24.0%-2.0%26.0%5.0%62.0%16.0%7.0%1.0%-14.0%-8.0%
NovoRapid® / NovoLog® (insulin aspart) — U.S. Operations sales (DKKm)2
1,790.001,483.001,866.002,027.003,365.001,514.001,060.001,621.001,312.001,019.00
NovoRapid® / NovoLog® (insulin aspart) — U.S. Operations sales growth at CER (%)(%)
-42.0%5.0%85.0%21.0%155.0%50.0%38.0%5.0%-19.0%-23.0%
NovoRapid® / NovoLog® (insulin aspart) — North America Operations sales [reported through FY2024] (DKKm)
3,397.001,549.001,097.001,656.001,358.001,065.00
NovoRapid® / NovoLog® (insulin aspart) — International Operations sales (DKKm)7
2,253.001,994.002,161.002,191.002,277.002,207.002,206.002,264.002,150.002,169.00
NovoRapid® / NovoLog® (insulin aspart) — International Operations sales growth at CER (%)(%)
3.0%-7.0%-2.0%-7.0%6.0%1.0%-2.0%-1.0%-9.0%3.0%
NovoRapid® / NovoLog® (insulin aspart) — EUCAN (Europe & Canada) sales (DKKm)1
1,102.00878.00888.00841.00
NovoRapid® / NovoLog® (insulin aspart) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
14.0%2.0%-8.0%-6.0%
NovoRapid® / NovoLog® (insulin aspart) — Emerging Markets sales (DKKm)1
624.00606.00727.00727.00
NovoRapid® / NovoLog® (insulin aspart) — Emerging Markets sales growth at CER (%)(%)
-7.0%-16.0%7.0%-1.0%
NovoRapid® / NovoLog® (insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
211.00236.00212.00236.00
NovoRapid® / NovoLog® (insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-17.0%14.0%-14.0%-2.0%
NovoRapid® / NovoLog® (insulin aspart) — Region China sales (DKKm)1
316.00274.00334.00387.00303.00360.00341.00470.00328.00370.00
NovoRapid® / NovoLog® (insulin aspart) — Region China sales growth at CER (%)(%)
12.0%-19.0%3.0%-19.0%-9.0%-3.0%-9.0%6.0%-3.0%-13.0%
NovoRapid® / NovoLog® (insulin aspart) — EMEA [reported through FY2024] sales (DKKm)1
1,468.001,418.001,387.001,372.001,351.001,339.00
NovoRapid® / NovoLog® (insulin aspart) — EMEA [reported through FY2024] sales growth at CER (%)(%)
9.0%6.0%3.0%-1.0%6.0%15.0%
NovoRapid® / NovoLog® (insulin aspart) — Rest of World [reported through FY2024] sales (DKKm)1
506.00429.00478.00422.00471.00460.00
NovoRapid® / NovoLog® (insulin aspart) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
10.0%-14.0%-8.0%-8.0%-48.0%-6.0%
Fiasp® (fast-acting insulin aspart) sales (DKKm)3
837.00632.00515.00834.00343.00394.00565.00567.00634.00574.00
Fiasp® (fast-acting insulin aspart) — Reported sales growth at CER (%)(%)
154.0%67.0%-5.0%44.0%-45.0%-32.0%26.0%11.0%31.0%25.0%
Fiasp® (fast-acting insulin aspart) — U.S. Operations sales (DKKm)2
368.00235.0070.00406.00-104.00-6.00144.00179.00215.00226.00
Fiasp® (fast-acting insulin aspart) — U.S. Operations sales growth at CER (%)(%)
0.0%0.0%-40.0%120.0%-149.0%-102.0%109.0%66.0%59.0%85.0%
Fiasp® (fast-acting insulin aspart) — North America Operations sales [reported through FY2024] (DKKm)
-92.006.00156.00190.00226.00237.00
Fiasp® (fast-acting insulin aspart) — International Operations sales (DKKm)7
469.00397.00445.00428.00435.00388.00409.00377.00408.00337.00
Fiasp® (fast-acting insulin aspart) — International Operations sales growth at CER (%)(%)
7.0%3.0%7.0%9.0%8.0%14.0%12.0%-4.0%21.0%4.0%
Fiasp® (fast-acting insulin aspart) — EUCAN (Europe & Canada) sales (DKKm)1
350.00311.00341.00312.00
Fiasp® (fast-acting insulin aspart) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
3.0%2.0%7.0%3.0%
Fiasp® (fast-acting insulin aspart) — Emerging Markets sales (DKKm)1
62.0034.0052.0062.00
Fiasp® (fast-acting insulin aspart) — Emerging Markets sales growth at CER (%)(%)
16.0%-18.0%8.0%49.0%
Fiasp® (fast-acting insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
57.0052.0052.0054.00
Fiasp® (fast-acting insulin aspart) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
29.0%30.0%4.0%15.0%
Fiasp® (fast-acting insulin aspart) — Region China sales (DKKm)1
0.000.000.000.000.000.000.000.000.000.00
Fiasp® (fast-acting insulin aspart) — Region China sales growth at CER (%)(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Fiasp® (fast-acting insulin aspart) — EMEA [reported through FY2024] sales (DKKm)1
353.00316.00316.00304.00346.00275.00
Fiasp® (fast-acting insulin aspart) — EMEA [reported through FY2024] sales growth at CER (%)(%)
2.0%15.0%2.0%-8.0%20.0%4.0%
Fiasp® (fast-acting insulin aspart) — Rest of World [reported through FY2024] sales (DKKm)1
82.0072.0093.0073.0062.0062.00
Fiasp® (fast-acting insulin aspart) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
40.0%13.0%67.0%17.0%24.0%5.0%
Fast-acting insulin — Reported sales growth at CER (%)(%)
3.0%44.0%-14.0%5.0%21.0%10.0%45.0%9.0%10.0%2.0%-9.0%-4.0%
Fast-acting insulin — Adjusted sales excl. 340B reversal (DKKm)2
4,691.003,955.004,880.004,109.004,542.005,052.006,017.004,150.003,868.004,487.004,142.003,808.00
Fast-acting insulin — Adjusted sales growth at CER (%)(%)
10.0%-16.0%-14.0%5.0%21.0%10.0%45.0%9.0%10.0%2.0%-9.0%-4.0%
Fast-acting insulin — U.S. 340B rebate provision reversal (DKKm)
0.002,924.00
Fast-acting insulin — U.S. Operations sales (DKKm)3
1,830.004,369.002,158.001,718.001,936.002,433.003,261.001,508.001,204.001,800.001,527.001,245.00
Fast-acting insulin — U.S. Operations sales growth at CER (%)(%)
15.0%-34.0%-28.0%22.0%71.0%31.0%113.0%22.0%44.0%9.0%-13.0%-14.0%
Fast-acting insulin — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
1,830.001,445.002,158.001,718.001,936.002,433.003,261.001,508.001,204.001,800.001,527.001,245.00
Fast-acting insulin — North America Operations sales [reported through FY2024] (DKKm)
3,305.001,555.001,253.001,846.001,584.001,302.00
Fast-acting insulin — International Operations sales (DKKm)7
2,861.002,510.002,722.002,391.002,606.002,619.002,712.002,595.002,615.002,641.002,558.002,506.00
Fast-acting insulin — International Operations sales growth at CER (%)(%)
7.0%1.0%4.0%-5.0%-1.0%-5.0%6.0%2.0%0.0%-1.0%-5.0%4.0%
Fast-acting insulin — EUCAN (Europe & Canada) sales (DKKm)1
1,293.001,243.001,452.001,189.001,229.001,153.00
Fast-acting insulin — EUCAN (Europe & Canada) sales growth at CER (%)(%)
5.0%8.0%11.0%2.0%-4.0%-4.0%
Fast-acting insulin — Emerging Markets sales (DKKm)1
958.00653.00686.00640.00779.00789.00
Fast-acting insulin — Emerging Markets sales growth at CER (%)(%)
13.0%-7.0%-6.0%-16.0%8.0%2.0%
Fast-acting insulin — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
264.00254.00268.00288.00264.00290.00
Fast-acting insulin — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
7.0%-2.0%-10.0%17.0%-11.0%0.0%
Fast-acting insulin — Region China sales (DKKm)1
346.00360.00316.00274.00334.00387.00303.00360.00341.00470.00328.00370.00
Fast-acting insulin — Region China sales growth at CER (%)(%)
0.0%-2.0%12.0%-19.0%3.0%-19.0%-9.0%-3.0%-9.0%6.0%-3.0%-13.0%
Fast-acting insulin — EMEA [reported through FY2024] sales (DKKm)1
1,821.001,734.001,703.001,676.001,697.001,614.00
Fast-acting insulin — EMEA [reported through FY2024] sales growth at CER (%)(%)
7.0%8.0%2.0%-2.0%9.0%13.0%
Fast-acting insulin — Rest of World [reported through FY2024] sales (DKKm)1
588.00501.00571.00495.00533.00522.00
Fast-acting insulin — Rest of World [reported through FY2024] sales growth at CER (%)(%)
13.0%-11.0%-1.0%-5.0%-42.0%-5.0%
Human insulin sales (DKKm)4
1,048.001,157.001,312.001,327.001,101.001,744.001,845.001,806.001,571.001,745.001,989.001,626.00
Human insulin — Reported sales growth at CER (%)(%)
-3.0%-28.0%-24.0%-23.0%-26.0%2.0%11.0%8.0%-22.0%-15.0%-14.0%-13.0%
Human insulin — Adjusted sales excl. 340B reversal (DKKm)2
1,048.001,063.001,312.001,327.001,101.001,744.001,845.001,806.001,571.001,745.001,989.001,626.00
Human insulin — Adjusted sales growth at CER (%)(%)
-2.0%-34.0%-24.0%-23.0%-26.0%2.0%11.0%8.0%-22.0%-15.0%-14.0%-13.0%
Human insulin — U.S. 340B rebate provision reversal (DKKm)
0.0094.00
Human insulin — U.S. Operations sales (DKKm)3
315.00411.00375.00470.00236.00334.00515.00378.00286.00356.00539.00206.00
Human insulin — U.S. Operations sales growth at CER (%)(%)
42.0%5.0%-21.0%30.0%-12.0%-9.0%77.0%25.0%-26.0%-17.0%-39.0%-48.0%
Human insulin — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
315.00317.00375.00470.00236.00334.00515.00378.00286.00356.00539.00206.00
Human insulin — North America Operations sales [reported through FY2024] (DKKm)
525.00388.00299.00367.00553.00219.00
Human insulin — International Operations sales (DKKm)7
733.00746.00937.00857.00865.001,410.001,320.001,418.001,272.001,378.001,436.001,407.00
Human insulin — International Operations sales growth at CER (%)(%)
-13.0%-43.0%-25.0%-36.0%-29.0%5.0%-2.0%4.0%-21.0%-15.0%-5.0%-3.0%
Human insulin — EUCAN (Europe & Canada) sales (DKKm)1
103.00110.00196.00162.00157.00190.00
Human insulin — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-34.0%-42.0%-8.0%-22.0%-28.0%-16.0%
Human insulin — Emerging Markets sales (DKKm)1
343.00300.00400.00379.00337.00714.00
Human insulin — Emerging Markets sales growth at CER (%)(%)
5.0%-54.0%-38.0%-47.0%-39.0%6.0%
Human insulin — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
155.00140.00157.00155.00219.00281.00
Human insulin — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-23.0%-43.0%-32.0%-31.0%-10.0%20.0%
Human insulin — Region China sales (DKKm)1
132.00196.00184.00161.00152.00225.00170.00214.00215.00207.00282.00256.00
Human insulin — Region China sales growth at CER (%)(%)
-18.0%-7.0%16.0%-21.0%-24.0%6.0%-41.0%-17.0%-23.0%-44.0%-9.0%-37.0%
Human insulin — EMEA [reported through FY2024] sales (DKKm)1
417.00380.00466.00499.00481.00440.00
Human insulin — EMEA [reported through FY2024] sales growth at CER (%)(%)
-7.0%-9.0%-3.0%-1.0%3.0%4.0%
Human insulin — Rest of World [reported through FY2024] sales (DKKm)1
733.00824.00591.00672.00673.00711.00
Human insulin — Rest of World [reported through FY2024] sales growth at CER (%)(%)
17.0%21.0%-30.0%-9.0%-9.0%17.0%
Total Insulin — Reported sales growth at CER (%)(%)
0.0%32.0%-10.0%1.0%5.0%3.0%36.0%10.0%11.0%9.0%-4.0%-5.0%
Total Insulin — Adjusted sales excl. 340B reversal (DKKm)2
12,941.0011,645.0013,401.0011,993.0012,746.0014,997.0015,887.0012,509.0012,612.0014,365.0011,980.0011,345.00
Total Insulin — Adjusted sales growth at CER (%)(%)
6.0%-17.0%-10.0%1.0%5.0%3.0%36.0%10.0%11.0%9.0%-4.0%-5.0%
Total Insulin — U.S. 340B rebate provision reversal (DKKm)
0.007,139.00
Total Insulin — U.S. Operations sales (DKKm)3
3,012.009,845.003,990.003,163.003,388.004,693.005,697.002,825.002,937.004,019.002,788.002,252.00
Total Insulin — U.S. Operations sales growth at CER (%)(%)
15.0%-36.0%-24.0%20.0%23.0%13.0%123.0%21.0%71.0%25.0%-25.0%-23.0%
Total Insulin — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
3,012.002,706.003,990.003,163.003,388.004,693.005,697.002,825.002,937.004,019.002,788.002,252.00
Total Insulin — North America Operations sales [reported through FY2024] (DKKm)
5,924.003,053.003,175.004,243.003,029.002,479.00
Total Insulin — International Operations sales (DKKm)7
9,929.008,939.009,411.008,830.009,358.0010,304.009,963.009,456.009,437.0010,122.008,951.008,866.00
Total Insulin — International Operations sales growth at CER (%)(%)
4.0%-8.0%-3.0%-4.0%-1.0%-1.0%13.0%7.0%1.0%5.0%5.0%2.0%
Total Insulin — EUCAN (Europe & Canada) sales (DKKm)1
3,131.003,112.003,447.003,102.003,218.003,143.00
Total Insulin — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-3.0%0.0%-3.0%-4.0%-7.0%-4.0%
Total Insulin — Emerging Markets sales (DKKm)1
2,932.002,084.002,298.002,091.002,446.002,911.00
Total Insulin — Emerging Markets sales growth at CER (%)(%)
10.0%-22.0%-9.0%-18.0%0.0%3.0%
Total Insulin — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
1,195.001,182.001,290.001,301.001,350.001,404.00
Total Insulin — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-4.0%-5.0%-8.0%3.0%-2.0%-3.0%
Total Insulin — Region China sales (DKKm)1
2,671.002,561.002,376.002,336.002,344.002,846.002,370.002,283.002,319.002,788.001,941.002,124.00
Total Insulin — Region China sales growth at CER (%)(%)
10.0%-5.0%8.0%8.0%6.0%0.0%20.0%7.0%7.0%14.0%4.0%-8.0%
Total Insulin — EMEA [reported through FY2024] sales (DKKm)1
4,863.004,602.004,728.004,826.004,512.004,392.00
Total Insulin — EMEA [reported through FY2024] sales growth at CER (%)(%)
9.0%6.0%4.0%1.0%4.0%10.0%
Total Insulin — Rest of World [reported through FY2024] sales (DKKm)1
2,730.002,571.002,390.002,508.002,498.002,350.00
Total Insulin — Rest of World [reported through FY2024] sales growth at CER (%)(%)
13.0%9.0%-9.0%1.0%8.0%-3.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) sales (DKKm)4
704.00560.00422.00421.00454.00473.00512.00492.00533.00583.00322.00594.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Reported sales growth at CER (%)(%)
50.0%25.0%-12.0%-11.0%-12.0%-20.0%-13.0%0.0%-9.0%-6.0%-3.0%-26.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Adjusted sales excl. 340B reversal (DKKm)2
704.00560.00422.00421.00454.00473.00512.00492.00533.00583.00322.00594.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Adjusted sales growth at CER (%)(%)
50.0%25.0%-12.0%-11.0%-12.0%-20.0%-13.0%0.0%-9.0%-6.0%-3.0%-26.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — U.S. 340B rebate provision reversal (DKKm)
0.000.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — U.S. Operations sales (DKKm)2
10.0020.0040.0018.0040.0041.0051.0057.0047.0058.00-149.00143.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — U.S. Operations sales growth at CER (%)(%)
-75.0%-46.0%-14.0%-65.0%-11.0%-33.0%-51.0%30.0%-19.0%-9.0%24.0%-15.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — North America Operations sales [reported through FY2024] (DKKm)
62.0070.0058.0074.00-134.00158.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — International Operations sales (DKKm)7
694.00540.00382.00403.00414.00432.00450.00422.00475.00509.00456.00436.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — International Operations sales growth at CER (%)(%)
62.0%32.0%-12.0%-3.0%-12.0%-19.0%-4.0%-3.0%-7.0%-6.0%-5.0%-27.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — EUCAN (Europe & Canada) sales (DKKm)1
124.00127.00129.00127.00131.00132.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-5.0%-4.0%-6.0%-6.0%-4.0%-7.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Emerging Markets sales (DKKm)1
61.0071.0060.0057.0073.0071.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Emerging Markets sales growth at CER (%)(%)
-16.0%8.0%-1.0%-3.0%-3.0%0.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
65.0062.0065.0060.0068.0070.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-1.0%-1.0%-12.0%-14.0%-5.0%6.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Region China sales (DKKm)1
444.00280.00128.00159.00142.00159.00174.00164.00196.00248.00187.00161.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Region China sales growth at CER (%)(%)
196.0%86.0%-21.0%3.0%-24.0%-37.0%-9.0%2.0%-22.0%-9.0%-9.0%-30.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — EMEA [reported through FY2024] sales (DKKm)1
169.00166.00179.00174.00165.00172.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — EMEA [reported through FY2024] sales growth at CER (%)(%)
-6.0%-4.0%19.0%9.0%4.0%2.0%
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Rest of World [reported through FY2024] sales (DKKm)1
107.0092.00100.0087.00104.00103.00
Other Diabetes care (NovoNorm®, GlucaGen®, needles) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
7.0%-10.0%-8.0%-18.0%-10.0%-59.0%
Total Diabetes Care — Reported sales growth at CER (%)(%)
-1.0%31.0%-6.0%8.0%7.0%8.0%17.0%14.0%26.0%24.0%38.0%26.0%
Total Diabetes Care — Adjusted sales excl. 340B reversal (DKKm)2
50,429.0044,936.0051,350.0049,149.0051,566.0055,044.0058,572.0047,936.0050,180.0049,930.0050,063.0042,574.00
Total Diabetes Care — Adjusted sales growth at CER (%)(%)
3.0%-12.0%-6.0%8.0%7.0%8.0%17.0%14.0%26.0%24.0%38.0%26.0%
Total Diabetes Care — U.S. 340B rebate provision reversal (DKKm)
0.0023,083.00
Total Diabetes Care — U.S. Operations sales (DKKm)3
25,825.0045,132.0028,549.0026,489.0027,820.0030,286.0034,125.0025,113.0026,602.0026,546.0028,945.0021,318.00
Total Diabetes Care — U.S. Operations sales growth at CER (%)(%)
4.0%-19.0%-9.0%12.0%10.0%10.0%17.0%19.0%49.0%35.0%56.0%29.0%
Total Diabetes Care — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
25,825.0022,049.0028,549.0026,489.0027,820.0030,286.0034,125.0025,113.0026,602.0026,546.0028,945.0021,318.00
Total Diabetes Care — North America Operations sales [reported through FY2024] (DKKm)
36,332.0027,223.0028,577.0028,680.0031,154.0023,099.00
Total Diabetes Care — International Operations sales (DKKm)7
24,604.0022,887.0022,801.0022,660.0023,746.0024,758.0022,240.0020,713.0021,603.0021,250.0018,909.0019,475.00
Total Diabetes Care — International Operations sales growth at CER (%)(%)
3.0%-4.0%-3.0%3.0%4.0%6.0%19.0%7.0%9.0%12.0%18.0%23.0%
Total Diabetes Care — EUCAN (Europe & Canada) sales (DKKm)1
11,947.0011,415.0011,586.0010,757.0011,274.0010,345.00
Total Diabetes Care — EUCAN (Europe & Canada) sales growth at CER (%)(%)
6.0%11.0%1.0%9.0%12.0%4.0%
Total Diabetes Care — Emerging Markets sales (DKKm)1
5,240.004,223.004,371.004,277.005,277.006,428.00
Total Diabetes Care — Emerging Markets sales growth at CER (%)(%)
-7.0%-30.0%-12.0%-14.0%5.0%9.0%
Total Diabetes Care — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
2,819.002,950.003,044.003,029.003,288.003,179.00
Total Diabetes Care — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-8.0%3.0%-1.0%8.0%4.0%5.0%
Total Diabetes Care — Region China sales (DKKm)1
4,598.004,299.003,800.004,597.003,907.004,806.004,083.004,472.004,796.004,439.003,397.004,106.00
Total Diabetes Care — Region China sales growth at CER (%)(%)
14.0%-5.0%0.0%9.0%-14.0%6.0%18.0%9.0%16.0%11.0%13.0%18.0%
Total Diabetes Care — EMEA [reported through FY2024] sales (DKKm)1
12,037.0010,532.0010,755.0010,942.009,683.009,876.00
Total Diabetes Care — EMEA [reported through FY2024] sales growth at CER (%)(%)
25.0%7.0%7.0%10.0%12.0%25.0%
Total Diabetes Care — Rest of World [reported through FY2024] sales (DKKm)1
6,120.005,709.006,052.005,869.005,829.005,493.00
Total Diabetes Care — Rest of World [reported through FY2024] sales growth at CER (%)(%)
10.0%7.0%8.0%18.0%31.0%24.0%
Obesity and Diabetes Care Segment Total sales (DKKm)4
73,581.0091,362.0073,795.0070,255.0071,938.0073,468.0079,978.0066,737.0064,084.0060,965.0061,292.0054,829.00
Obesity and Diabetes Care Segment Total — Reported sales growth at CER (%)(%)
3.0%32.0%-2.0%11.0%17.0%19.0%31.0%23.0%27.0%27.0%48.0%45.0%
Obesity and Diabetes Care Segment Total — Adjusted sales excl. 340B reversal (DKKm)2
73,581.0065,848.0073,795.0070,255.0071,938.0073,468.0079,978.0066,737.0064,084.0060,965.0061,292.0054,829.00
Obesity and Diabetes Care Segment Total — Adjusted sales growth at CER (%)(%)
7.0%-4.0%-2.0%11.0%17.0%19.0%31.0%23.0%27.0%27.0%48.0%45.0%
Obesity and Diabetes Care Segment Total — U.S. 340B rebate provision reversal (DKKm)
0.0025,514.00
Obesity and Diabetes Care Segment Total — U.S. Operations sales (DKKm)3
38,649.0059,315.0042,311.0039,111.0040,780.0042,225.0049,566.0037,690.0036,901.0034,776.0037,697.0031,396.00
Obesity and Diabetes Care Segment Total — U.S. Operations sales growth at CER (%)(%)
4.0%-11.0%-7.0%10.0%16.0%18.0%31.0%21.0%41.0%37.0%71.0%65.0%
Obesity and Diabetes Care Segment Total — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
38,649.0033,801.0042,311.0039,111.0040,780.0042,225.0049,566.0037,690.0036,901.0034,776.0037,697.0031,396.00
Obesity and Diabetes Care Segment Total — North America Operations sales [reported through FY2024] (DKKm)
52,366.0040,275.0039,231.0037,098.0040,087.0033,324.00
Obesity and Diabetes Care Segment Total — International Operations sales (DKKm)7
34,932.0032,047.0031,484.0031,144.0031,158.0031,243.0027,612.0026,462.0024,853.0023,867.0021,205.0021,505.00
Obesity and Diabetes Care Segment Total — International Operations sales growth at CER (%)(%)
11.0%6.0%8.0%11.0%19.0%20.0%32.0%24.0%14.0%14.0%19.0%24.0%
Obesity and Diabetes Care Segment Total — EUCAN (Europe & Canada) sales (DKKm)1
17,855.0016,539.0016,670.0015,440.0015,159.0013,520.00
Obesity and Diabetes Care Segment Total — EUCAN (Europe & Canada) sales growth at CER (%)(%)
18.0%24.0%13.0%22.0%21.0%14.0%
Obesity and Diabetes Care Segment Total — Emerging Markets sales (DKKm)1
7,714.006,176.006,657.006,069.006,877.008,088.00
Obesity and Diabetes Care Segment Total — Emerging Markets sales growth at CER (%)(%)
5.0%-20.0%8.0%-16.0%20.0%27.0%
Obesity and Diabetes Care Segment Total — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
4,430.004,617.004,512.004,921.005,057.004,125.00
Obesity and Diabetes Care Segment Total — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-9.0%22.0%4.0%35.0%46.0%26.0%
Obesity and Diabetes Care Segment Total — Region China sales (DKKm)1
4,933.004,715.003,645.004,714.004,065.005,510.004,137.004,660.004,827.004,464.003,414.004,135.00
Obesity and Diabetes Care Segment Total — Region China sales growth at CER (%)(%)
18.0%-9.0%-5.0%7.0%-11.0%21.0%19.0%13.0%15.0%11.0%12.0%17.0%
Obesity and Diabetes Care Segment Total — EMEA [reported through FY2024] sales (DKKm)1
15,237.0013,354.0013,189.0012,919.0011,393.0011,219.00
Obesity and Diabetes Care Segment Total — EMEA [reported through FY2024] sales growth at CER (%)(%)
34.0%20.0%15.0%15.0%18.0%26.0%
Obesity and Diabetes Care Segment Total — Rest of World [reported through FY2024] sales (DKKm)1
8,238.008,448.006,837.006,484.006,398.006,151.00
Obesity and Diabetes Care Segment Total — Rest of World [reported through FY2024] sales growth at CER (%)(%)
35.0%41.0%11.0%15.0%25.0%24.0%
Rare Disease Segment Total sales (DKKm)7
4,907.005,461.005,349.004,721.004,919.004,619.005,705.004,574.003,976.004,384.004,571.003,902.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) sales (DKKm)7
2,896.002,633.003,019.002,919.003,096.002,921.003,398.002,988.002,864.002,888.002,934.002,957.00
NovoSeven® (recombinant factor VIIa) sales (DKKm)3
1,803.001,653.001,991.001,879.002,226.002,003.001,802.001,952.001,985.002,078.00
NovoSeven® (recombinant factor VIIa) — Reported sales growth at CER (%)(%)
-13.0%-13.0%16.0%-5.0%12.0%-3.0%0.0%-6.0%6.0%4.0%
NovoSeven® (recombinant factor VIIa) — U.S. Operations sales (DKKm)2
779.00744.00986.00993.001,103.001,176.00932.00924.001,217.001,037.00
NovoSeven® (recombinant factor VIIa) — U.S. Operations sales growth at CER (%)(%)
-23.0%-32.0%11.0%4.0%-10.0%14.0%13.0%-7.0%32.0%30.0%
NovoSeven® (recombinant factor VIIa) — North America Operations sales [reported through FY2024] (DKKm)
1,121.001,189.00970.00968.001,241.001,074.00
NovoSeven® (recombinant factor VIIa) — International Operations sales (DKKm)7
1,024.00909.001,005.00886.001,105.00814.00832.00984.00744.001,004.00
NovoSeven® (recombinant factor VIIa) — International Operations sales growth at CER (%)(%)
-4.0%15.0%21.0%-14.0%50.0%-19.0%-13.0%-9.0%-22.0%-14.0%
NovoSeven® (recombinant factor VIIa) — EUCAN (Europe & Canada) sales (DKKm)1
465.00391.00411.00384.00
NovoSeven® (recombinant factor VIIa) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
10.0%8.0%2.0%-9.0%
NovoSeven® (recombinant factor VIIa) — Emerging Markets sales (DKKm)1
407.00300.00334.00366.00
NovoSeven® (recombinant factor VIIa) — Emerging Markets sales growth at CER (%)(%)
-4.0%-7.0%11.0%-22.0%
NovoSeven® (recombinant factor VIIa) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
100.0098.00133.00120.00
NovoSeven® (recombinant factor VIIa) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-33.0%7.0%9.0%-3.0%
NovoSeven® (recombinant factor VIIa) — Region China sales (DKKm)1
52.00120.00127.0016.0069.0018.0011.0012.0031.0074.00
NovoSeven® (recombinant factor VIIa) — Region China sales growth at CER (%)(%)
-19.0%0.0%0.0%25.0%119.0%-76.0%0.0%-37.0%52.0%-77.0%
NovoSeven® (recombinant factor VIIa) — EMEA [reported through FY2024] sales (DKKm)1
597.00487.00486.00598.00470.00536.00
NovoSeven® (recombinant factor VIIa) — EMEA [reported through FY2024] sales growth at CER (%)(%)
27.0%-9.0%-22.0%-8.0%-15.0%-6.0%
NovoSeven® (recombinant factor VIIa) — Rest of World [reported through FY2024] sales (DKKm)1
439.00309.00335.00374.00243.00394.00
NovoSeven® (recombinant factor VIIa) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
86.0%-23.0%3.0%-8.0%-37.0%52.0%
Haemophilia A (NovoEight®, Esperoct®) sales (DKKm)3
638.00638.00584.00554.00670.00568.00613.00603.00525.00549.00
Haemophilia A (NovoEight®, Esperoct®) — Reported sales growth at CER (%)(%)
0.0%18.0%-1.0%-10.0%29.0%4.0%-11.0%-8.0%-19.0%13.0%
Haemophilia A (NovoEight®, Esperoct®) — U.S. Operations sales (DKKm)2
119.0094.0095.0091.00126.00124.00102.00185.0054.00142.00
Haemophilia A (NovoEight®, Esperoct®) — U.S. Operations sales growth at CER (%)(%)
1.0%-20.0%-2.0%-52.0%128.0%-11.0%-28.0%38.0%-71.0%25.0%
Haemophilia A (NovoEight®, Esperoct®) — North America Operations sales [reported through FY2024] (DKKm)
129.00128.00104.00187.0056.00142.00
Haemophilia A (NovoEight®, Esperoct®) — International Operations sales (DKKm)7
519.00544.00489.00463.00541.00440.00509.00416.00469.00407.00
Haemophilia A (NovoEight®, Esperoct®) — International Operations sales growth at CER (%)(%)
0.0%28.0%-1.0%9.0%17.0%8.0%-6.0%-19.0%6.0%12.0%
Haemophilia A (NovoEight®, Esperoct®) — EUCAN (Europe & Canada) sales (DKKm)1
245.00241.00248.00253.00
Haemophilia A (NovoEight®, Esperoct®) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-18.0%-10.0%-17.0%3.0%
Haemophilia A (NovoEight®, Esperoct®) — Emerging Markets sales (DKKm)1
140.00108.0090.0072.00
Haemophilia A (NovoEight®, Esperoct®) — Emerging Markets sales growth at CER (%)(%)
48.0%25.0%94.0%-30.0%
Haemophilia A (NovoEight®, Esperoct®) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
55.0077.0065.0056.00
Haemophilia A (NovoEight®, Esperoct®) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
0.0%46.0%51.0%-2.0%
Haemophilia A (NovoEight®, Esperoct®) — Region China sales (DKKm)1
79.00118.0086.0082.0079.0023.00116.0018.00-19.0014.00
Haemophilia A (NovoEight®, Esperoct®) — Region China sales growth at CER (%)(%)
8.0%448.0%-23.0%344.0%0.0%64.0%-5.0%-83.0%-200.0%40.0%
Haemophilia A (NovoEight®, Esperoct®) — EMEA [reported through FY2024] sales (DKKm)1
328.00293.00328.00282.00317.00318.00
Haemophilia A (NovoEight®, Esperoct®) — EMEA [reported through FY2024] sales growth at CER (%)(%)
3.0%-8.0%10.0%-15.0%13.0%17.0%
Haemophilia A (NovoEight®, Esperoct®) — Rest of World [reported through FY2024] sales (DKKm)1
134.00124.0065.00116.00171.0075.00
Haemophilia A (NovoEight®, Esperoct®) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
-18.0%67.0%-47.0%51.0%28.0%-9.0%
Haemophilia B (Refixia®) sales (DKKm)3
356.00376.00338.00342.00378.00305.00361.00262.00329.00285.00
Haemophilia B (Refixia®) — Reported sales growth at CER (%)(%)
1.0%29.0%-4.0%27.0%15.0%6.0%45.0%36.0%50.0%58.0%
Haemophilia B (Refixia®) — U.S. Operations sales (DKKm)2
142.00143.00118.00142.00151.0092.00158.0085.00126.0091.00
Haemophilia B (Refixia®) — U.S. Operations sales growth at CER (%)(%)
3.0%62.0%-22.0%64.0%18.0%3.0%116.0%85.0%159.0%143.0%
Haemophilia B (Refixia®) — North America Operations sales [reported through FY2024] (DKKm)
196.00139.00201.00121.00158.00138.00
Haemophilia B (Refixia®) — International Operations sales (DKKm)7
214.00233.00220.00200.00182.00166.00160.00141.00171.00147.00
Haemophilia B (Refixia®) — International Operations sales growth at CER (%)(%)
0.0%15.0%10.0%10.0%7.0%10.0%12.0%21.0%23.0%31.0%
Haemophilia B (Refixia®) — EUCAN (Europe & Canada) sales (DKKm)1
150.00168.00157.00135.00
Haemophilia B (Refixia®) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-12.0%11.0%5.0%2.0%
Haemophilia B (Refixia®) — Emerging Markets sales (DKKm)1
29.0016.0017.0021.00
Haemophilia B (Refixia®) — Emerging Markets sales growth at CER (%)(%)
209.0%50.0%55.0%0.0%
Haemophilia B (Refixia®) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
31.0045.0042.0039.00
Haemophilia B (Refixia®) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
-10.0%21.0%23.0%3.0%
Haemophilia B (Refixia®) — Region China sales (DKKm)1
4.004.004.005.003.005.004.005.004.003.00
Haemophilia B (Refixia®) — Region China sales growth at CER (%)(%)
33.0%-20.0%0.0%0.0%-25.0%67.0%67.0%67.0%0.0%33.0%
Haemophilia B (Refixia®) — EMEA [reported through FY2024] sales (DKKm)1
126.00109.00110.0091.00115.0094.00
Haemophilia B (Refixia®) — EMEA [reported through FY2024] sales growth at CER (%)(%)
9.0%15.0%20.0%18.0%34.0%27.0%
Haemophilia B (Refixia®) — Rest of World [reported through FY2024] sales (DKKm)1
53.0052.0046.0045.0052.0050.00
Haemophilia B (Refixia®) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
6.0%-2.0%-6.0%22.0%6.0%40.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Reported sales growth at CER (%)(%)
-4.0%-3.0%-5.0%3.0%13.0%-1.0%16.0%1.0%1.0%-4.0%4.0%9.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Adjusted sales excl. 340B reversal (DKKm)2
2,896.002,633.003,019.002,919.003,096.002,921.003,398.002,988.002,864.002,888.002,934.002,957.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Adjusted sales growth at CER (%)(%)
-4.0%-3.0%-5.0%3.0%13.0%-1.0%16.0%1.0%1.0%-4.0%4.0%9.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — U.S. 340B rebate provision reversal (DKKm)
0.000.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — U.S. Operations sales (DKKm)2
1,294.001,002.001,160.001,152.001,296.001,319.001,446.001,456.001,255.001,230.001,465.001,282.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — U.S. Operations sales growth at CER (%)(%)
4.0%-16.0%-12.0%-16.0%8.0%4.0%-2.0%15.0%13.0%1.0%19.0%30.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — North America Operations sales [reported through FY2024] (DKKm)
1,516.001,524.001,341.001,315.001,525.001,370.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — International Operations sales (DKKm)7
1,602.001,631.001,859.001,767.001,800.001,602.001,882.001,464.001,523.001,573.001,409.001,587.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — International Operations sales growth at CER (%)(%)
-9.0%7.0%0.0%21.0%16.0%-4.0%35.0%-8.0%-9.0%-10.0%-9.0%-4.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — EUCAN (Europe & Canada) sales (DKKm)1
790.00843.00887.00823.00838.00792.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
-6.0%7.0%-3.0%4.0%-2.0%-2.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Emerging Markets sales (DKKm)1
471.00481.00588.00434.00458.00466.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Emerging Markets sales growth at CER (%)(%)
4.0%12.0%10.0%0.0%25.0%-22.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
315.00257.00249.00268.00287.00241.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
20.0%20.0%-9.0%37.0%36.0%7.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Region China sales (DKKm)1
26.0050.00135.00242.00217.00103.00151.0046.00131.0035.0016.0091.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Region China sales growth at CER (%)(%)
-87.0%-50.0%-4.0%461.0%73.0%186.0%0.0%-49.0%-3.0%-72.0%-73.0%-71.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — EMEA [reported through FY2024] sales (DKKm)1
1,072.00918.00938.00996.00919.00971.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — EMEA [reported through FY2024] sales growth at CER (%)(%)
17.0%-5.0%-9.0%-9.0%-2.0%4.0%
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Rest of World [reported through FY2024] sales (DKKm)1
659.00500.00454.00542.00474.00525.00
Rare blood disorders (NovoSeven®, Haemophilia A/B, Alhemo®) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
44.0%-6.0%-10.0%2.0%-17.0%36.0%
Rare endocrine disorders (Norditropin®, Sogroya®) sales (DKKm)4
1,538.002,393.001,834.001,393.001,420.001,312.001,923.001,227.00730.001,113.001,264.00542.00
Rare endocrine disorders (Norditropin®, Sogroya®) — Reported sales growth at CER (%)(%)
13.0%93.0%2.0%20.0%100.0%14.0%53.0%126.0%-18.0%1.0%-21.0%-71.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — Adjusted sales excl. 340B reversal (DKKm)2
1,538.001,147.001,834.001,393.001,420.001,312.001,923.001,227.00730.001,113.001,264.00542.00
Rare endocrine disorders (Norditropin®, Sogroya®) — Adjusted sales growth at CER (%)(%)
24.0%-5.0%2.0%20.0%100.0%14.0%53.0%126.0%-18.0%1.0%-21.0%-71.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — U.S. 340B rebate provision reversal (DKKm)
0.001,246.00
Rare endocrine disorders (Norditropin®, Sogroya®) — U.S. Operations sales (DKKm)3
812.001,742.001,131.00817.00816.00714.001,323.00675.00196.00728.00887.00192.00
Rare endocrine disorders (Norditropin®, Sogroya®) — U.S. Operations sales growth at CER (%)(%)
22.0%-23.0%-8.0%28.0%335.0%-5.0%49.0%256.0%-29.0%78.0%118.0%-62.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
812.00496.001,131.00817.00816.00714.001,323.00675.00196.00728.00887.00192.00
Rare endocrine disorders (Norditropin®, Sogroya®) — North America Operations sales [reported through FY2024] (DKKm)
1,334.00685.00206.00736.00898.00198.00
Rare endocrine disorders (Norditropin®, Sogroya®) — International Operations sales (DKKm)7
726.00651.00703.00576.00604.00598.00589.00542.00524.00377.00366.00344.00
Rare endocrine disorders (Norditropin®, Sogroya®) — International Operations sales growth at CER (%)(%)
26.0%17.0%24.0%10.0%14.0%51.0%65.0%56.0%-14.0%-44.0%-72.0%-75.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — EUCAN (Europe & Canada) sales (DKKm)1
321.00292.00303.00255.00230.00214.00
Rare endocrine disorders (Norditropin®, Sogroya®) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
40.0%36.0%36.0%16.0%31.0%6.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — Emerging Markets sales (DKKm)1
160.00143.00169.0088.00145.00192.00
Rare endocrine disorders (Norditropin®, Sogroya®) — Emerging Markets sales growth at CER (%)(%)
16.0%-15.0%45.0%-27.0%-19.0%366.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
236.00209.00227.00227.00223.00186.00
Rare endocrine disorders (Norditropin®, Sogroya®) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
18.0%27.0%16.0%32.0%33.0%29.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — Region China sales (DKKm)1
9.007.004.006.006.006.0034.002.002.003.00-13.00115.00
Rare endocrine disorders (Norditropin®, Sogroya®) — Region China sales growth at CER (%)(%)
50.0%17.0%-91.0%200.0%250.0%100.0%0.0%-98.0%-97.0%-94.0%-120.0%106.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — EMEA [reported through FY2024] sales (DKKm)1
275.00277.00277.00209.00190.00177.00
Rare endocrine disorders (Norditropin®, Sogroya®) — EMEA [reported through FY2024] sales growth at CER (%)(%)
44.0%56.0%71.0%22.0%-66.0%-69.0%
Rare endocrine disorders (Norditropin®, Sogroya®) — Rest of World [reported through FY2024] sales (DKKm)1
280.00263.00245.00165.00189.0052.00
Rare endocrine disorders (Norditropin®, Sogroya®) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
58.0%396.0%-36.0%-62.0%-70.0%-100.0%
Other Rare disease (Vagifem®, Activelle®) sales (DKKm)4
473.00435.00496.00409.00403.00386.00384.00359.00382.00383.00373.00403.00
Other Rare disease (Vagifem®, Activelle®) — Reported sales growth at CER (%)(%)
18.0%18.0%36.0%19.0%8.0%1.0%2.0%-11.0%2.0%-2.0%5.0%1.0%
Other Rare disease (Vagifem®, Activelle®) — Adjusted sales excl. 340B reversal (DKKm)2
473.00435.00496.00409.00403.00386.00384.00359.00382.00383.00373.00403.00
Other Rare disease (Vagifem®, Activelle®) — Adjusted sales growth at CER (%)(%)
18.0%18.0%36.0%19.0%8.0%1.0%2.0%-11.0%2.0%-2.0%5.0%1.0%
Other Rare disease (Vagifem®, Activelle®) — U.S. 340B rebate provision reversal (DKKm)
0.000.00
Other Rare disease (Vagifem®, Activelle®) — U.S. Operations sales (DKKm)2
114.0086.00141.0064.0071.0058.0037.0023.0052.0048.0018.0066.00
Other Rare disease (Vagifem®, Activelle®) — U.S. Operations sales growth at CER (%)(%)
65.0%67.0%305.0%205.0%44.0%17.0%102.0%-65.0%-20.0%-13.0%-47.0%-40.0%
Other Rare disease (Vagifem®, Activelle®) — North America Operations sales [reported through FY2024] (DKKm)
148.00114.00152.00131.00111.00156.00
Other Rare disease (Vagifem®, Activelle®) — International Operations sales (DKKm)7
359.00349.00355.00345.00332.00328.00236.00245.00230.00252.00262.00247.00
Other Rare disease (Vagifem®, Activelle®) — International Operations sales growth at CER (%)(%)
8.0%9.0%7.0%7.0%3.0%-2.0%-12.0%-2.0%2.0%-4.0%13.0%16.0%
Other Rare disease (Vagifem®, Activelle®) — EUCAN (Europe & Canada) sales (DKKm)1
240.00244.00252.00249.00220.00239.00
Other Rare disease (Vagifem®, Activelle®) — EUCAN (Europe & Canada) sales growth at CER (%)(%)
10.0%5.0%4.0%10.0%-5.0%8.0%
Other Rare disease (Vagifem®, Activelle®) — Emerging Markets sales (DKKm)1
68.0061.0053.0044.0064.0044.00
Other Rare disease (Vagifem®, Activelle®) — Emerging Markets sales growth at CER (%)(%)
3.0%36.0%56.0%-18.0%64.0%-33.0%
Other Rare disease (Vagifem®, Activelle®) — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
49.0042.0050.0050.0048.0042.00
Other Rare disease (Vagifem®, Activelle®) — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
6.0%5.0%-7.0%10.0%-2.0%-2.0%
Other Rare disease (Vagifem®, Activelle®) — Region China sales (DKKm)1
2.002.000.002.000.003.002.000.003.004.001.000.00
Other Rare disease (Vagifem®, Activelle®) — Region China sales growth at CER (%)(%)
0.0%-33.0%-100.0%0.0%-67.0%-50.0%100.0%0.0%50.0%100.0%0.0%-100.0%
Other Rare disease (Vagifem®, Activelle®) — EMEA [reported through FY2024] sales (DKKm)1
175.00187.00177.00202.00204.00196.00
Other Rare disease (Vagifem®, Activelle®) — EMEA [reported through FY2024] sales growth at CER (%)(%)
-17.0%-5.0%4.0%-4.0%16.0%13.0%
Other Rare disease (Vagifem®, Activelle®) — Rest of World [reported through FY2024] sales (DKKm)1
59.0058.0050.0046.0057.0051.00
Other Rare disease (Vagifem®, Activelle®) — Rest of World [reported through FY2024] sales growth at CER (%)(%)
5.0%12.0%-7.0%-9.0%3.0%33.0%
Rare Disease Segment Total — Reported sales growth at CER (%)(%)
3.0%26.0%0.0%9.0%28.0%3.0%25.0%17.0%-3.0%-3.0%-5.0%-20.0%
Rare Disease Segment Total — Adjusted sales excl. 340B reversal (DKKm)2
4,907.004,215.005,349.004,721.004,919.004,619.005,705.004,574.003,976.004,384.004,571.003,902.00
Rare Disease Segment Total — Adjusted sales growth at CER (%)(%)
6.0%-2.0%0.0%9.0%28.0%3.0%25.0%17.0%-3.0%-3.0%-5.0%-20.0%
Rare Disease Segment Total — U.S. 340B rebate provision reversal (DKKm)
0.001,246.00
Rare Disease Segment Total — U.S. Operations sales (DKKm)3
2,220.002,830.002,432.002,033.002,183.002,091.002,806.002,154.001,503.002,006.002,370.001,540.00
Rare Disease Segment Total — U.S. Operations sales growth at CER (%)(%)
12.0%-16.0%-6.0%0.0%52.0%1.0%18.0%41.0%4.0%19.0%41.0%-4.0%
Rare Disease Segment Total — U.S. Operations adjusted sales excl. 340B reversal (DKKm)
2,220.001,584.002,432.002,033.002,183.002,091.002,806.002,154.001,503.002,006.002,370.001,540.00
Rare Disease Segment Total — North America Operations sales [reported through FY2024] (DKKm)
2,998.002,323.001,699.002,182.002,534.001,724.00
Rare Disease Segment Total — International Operations sales (DKKm)7
2,687.002,631.002,917.002,688.002,736.002,528.002,707.002,251.002,277.002,202.002,037.002,178.00
Rare Disease Segment Total — International Operations sales growth at CER (%)(%)
1.0%9.0%6.0%16.0%14.0%5.0%35.0%3.0%-9.0%-18.0%-32.0%-30.0%
Rare Disease Segment Total — EUCAN (Europe & Canada) sales (DKKm)1
1,351.001,379.001,442.001,327.001,288.001,245.00
Rare Disease Segment Total — EUCAN (Europe & Canada) sales growth at CER (%)(%)
5.0%12.0%5.0%7.0%2.0%1.0%
Rare Disease Segment Total — Emerging Markets sales (DKKm)1
699.00685.00810.00566.00667.00702.00
Rare Disease Segment Total — Emerging Markets sales growth at CER (%)(%)
6.0%6.0%19.0%-8.0%14.0%-2.0%
Rare Disease Segment Total — APAC (Japan, Korea, Oceania & SE Asia) sales (DKKm)1
600.00508.00526.00545.00558.00469.00
Rare Disease Segment Total — APAC (Japan, Korea, Oceania & SE Asia) sales growth at CER (%)(%)
18.0%22.0%1.0%32.0%31.0%14.0%
Rare Disease Segment Total — Region China sales (DKKm)1
37.0059.00139.00250.00223.00112.00187.0048.00136.0042.004.00206.00
Rare Disease Segment Total — Region China sales growth at CER (%)(%)
-82.0%-46.0%-21.0%456.0%73.0%157.0%0.0%-77.0%-31.0%-77.0%-101.0%-46.0%
Rare Disease Segment Total — EMEA [reported through FY2024] sales (DKKm)1
1,522.001,382.001,392.001,407.001,313.001,344.00
Rare Disease Segment Total — EMEA [reported through FY2024] sales growth at CER (%)(%)
15.0%3.0%2.0%-5.0%-21.0%-19.0%
Rare Disease Segment Total — Rest of World [reported through FY2024] sales (DKKm)1
998.00821.00749.00753.00720.00628.00
Rare Disease Segment Total — Rest of World [reported through FY2024] sales growth at CER (%)(%)
45.0%29.0%-20.0%-27.0%-41.0%-42.0%
Total Segment Operating Profit (EBIT) (DKKm)2
27,061.0059,618.0031,736.0023,682.0033,449.0038,791.0036,737.0033,822.0025,934.0031,846.0026,766.0026,913.00
Obesity and Diabetes care — Segment operating profit (EBIT) (DKKm)
28,356.0058,000.0031,046.0024,222.0032,931.0038,247.0036,044.0033,473.0026,984.0031,218.0026,032.0026,721.00
Rare disease — Segment operating profit (EBIT) (DKKm)
-1,295.001,618.00690.00-540.00518.00544.00693.00349.00-1,050.00628.00734.00192.00
Total patients reached with Obesity and Diabetes care products (MAT, millions)(M)4
46.545.345.645.645.745.745.243.942.141.841.640.6
Patients reached with Obesity care products (MAT, millions)(M)
4.904.103.603.202.902.602.201.801.401.201.101
Patients reached with Diabetes care products (MAT, millions)(M)
41.641.24242.442.843.14342.140.740.640.539.6
Vulnerable patients reached with Diabetes care products in LMICs / affordability programmes (MAT, millions)(M)
6.606.507.107.207.508.108.408.508.608.80
Children reached through Changing Diabetes® in Children programme (cumulative)
90,43286,40781,94676,69372,76068,93564,74359,29456,82154,09252,24946,522
Total greenhouse gas (GHG) emissions — Scope 1, 2 & full Scope 3 (1,000 tonnes CO2e)3
629.00614.00769.00610.00644.00667.00708.00552.00515.00486.00-738.00893.00
Scope 1 direct GHG emissions (1,000 tonnes CO2e)
27.0034.0031.0028.0028.0033.0026.0021.0019.0019.0024.0018.00
Scope 2 indirect GHG emissions — market-based (1,000 tonnes CO2e)
14.0016.0015.0016.0015.0017.005.001.004.006.004.004.00
Scope 3 value-chain GHG emissions (1,000 tonnes CO2e)
588.00564.00723.00566.00601.00617.00677.00530.00492.00461.00
Absolute plastic footprint (MAT, tonnes)1
16,289.0016,166.0016,463.0015,389.0017,063.0017,115.0017,128.0015,205.0014,916.0015,076.00
Plastic footprint per patient (MAT, kg/patient)
0.350.360.360.340.370.370.380.350.350.35
Research and development (R&D) costs (DKKm)1
17,787.0010,284.0014,648.0015,393.0011,690.0010,308.0013,802.009,488.0016,166.008,606.0010,460.008,128.00
R&D costs as % of net sales (%)(%)
18.5%20.5%15.2%13.2%16.1%13.3%23.8%13.2%15.9%13.8%
Total inventories — net carrying amount (DKKm)
51,352.0051,352.0049,623.0047,504.0045,652.0042,853.0040,849.0037,944.0036,356.0033,600.0031,811.0029,534.00
Property, plant and equipment (PP&E) — net carrying amount (DKKm)
231,758.00219,974.00208,378.00193,244.00180,758.00172,376.00161,680.00119,832.00109,980.0098,230.0090,961.0081,461.00
Intangible assets — net carrying amount (DKKm)
102,167.00110,033.00110,208.00106,587.00107,866.00109,379.00111,090.0054,488.0055,501.0059,640.0060,406.0055,726.00
Net sales — IFRS reported (DKKm)2
78,488.0096,823.0079,144.0074,976.0076,857.0078,087.0085,683.0071,311.0068,060.0065,349.0065,863.0058,731.00
Net sales growth at CER — IFRS reported (%)(%)
3.0%32.0%-2.0%11.0%18.0%18.0%30.0%23.0%25.0%24.0%43.0%38.0%
Adjusted net sales excl. U.S. 340B provision reversal (DKKm)2
78,488.0070,063.0079,144.0074,976.0076,857.0078,087.0085,683.0071,311.0068,060.0065,349.0065,863.0058,731.00
Adjusted net sales growth at CER (%)(%)
7.0%-4.0%-2.0%11.0%18.0%18.0%30.0%23.0%25.0%24.0%43.0%38.0%
Total U.S. 340B Drug Pricing Program rebate provision reversal (DKKm)
0.0026,760.00
Gross profit — IFRS reported (DKKm)4
61,388.0083,225.0063,996.0057,072.0064,011.0065,197.0072,659.0060,003.0057,786.0055,433.0055,849.0049,018.00
Gross margin — IFRS reported (%)(%)
78.2%86.0%80.9%76.1%83.3%83.5%84.8%84.1%84.9%84.8%84.8%83.5%
Cost of goods sold (DKKm)
17,100.0013,598.0012,846.0012,890.0011,308.0010,274.009,916.009,713.00
Adjusted gross profit excl. 340B reversal (DKKm)
61,388.0056,465.00
Adjusted gross margin excl. 340B reversal (%)(%)
78.2%81.0%
Operating profit (EBIT) — IFRS reported (DKKm)6
27,061.0059,618.0031,736.0023,682.0033,449.0038,791.0036,737.0033,822.0025,934.0031,846.0026,766.0026,913.00
Operating margin (EBIT margin) — IFRS reported (%)(%)
34.5%62.0%40.1%31.6%43.5%49.7%42.9%47.4%38.1%48.7%40.6%45.8%
Adjusted operating profit (EBIT) excl. 340B reversal & major impairments (DKKm)
33,389.0032,858.00
Adjusted operating margin (%)(%)
42.5%47.0%
Sales and distribution costs (DKKm)1
14,997.0012,077.0015,889.0015,996.0017,533.0014,892.0018,701.0015,210.0014,934.0013,256.0017,170.0012,819.00
Sales and distribution costs (% of net sales)(%)
20.1%21.3%22.8%19.1%21.8%21.3%21.9%20.3%26.1%21.8%
Administrative costs (DKKm)1
1,309.001,140.001,549.001,884.001,316.001,220.001,580.001,382.001,157.001,157.001,456.001,256.00
Administrative costs (% of net sales)(%)
2.0%2.5%1.7%1.6%1.8%1.9%1.7%1.8%2.2%2.1%
Other operating income and expenses, net (DKKm)
-234.00-106.00-174.00-117.00-23.0014.00-1,839.00-101.00405.00-568.003.0098.00
EBITDA (DKKm)1
37,365.0063,154.0037,298.0031,439.0038,282.0042,621.0041,935.0035,972.0034,779.0034,760.0029,758.0029,438.00
Depreciation, amortisation and impairment losses (DKKm)
10,304.003,536.005,562.007,757.004,833.003,830.005,198.002,150.008,845.002,914.002,992.002,525.00
Net profit — IFRS reported (DKKm)9
20,989.0048,557.0026,891.0020,006.0026,503.0029,034.0028,230.0027,301.0020,050.0025,407.0021,963.0022,478.00
Adjusted net profit (Non-IFRS, DKKm)
27,421.0029,479.0028,659.0029,179.0028,265.0030,304.0030,516.0027,798.0025,795.0026,449.00
Profit before income taxes (DKKm)
26,875.0062,172.0034,185.0025,517.0033,805.0037,033.0035,557.0034,384.0025,332.0031,918.0027,620.0028,063.00
Income taxes (DKKm)
5,886.0013,615.007,294.005,511.007,302.007,999.007,327.007,083.005,282.006,511.005,657.005,585.00
Financial income (DKKm)
1,314.006,053.00614.00307.005,314.003,425.003,913.00-821.00960.002,146.00-944.003,318.00
Financial expenses (DKKm)
-1,500.00-3,499.001,835.001,528.00-4,958.00-5,183.00-5,093.001,383.00-1,562.00-2,074.001,798.00-2,168.00
Diluted earnings per share / ADR (DKK)
4.7510.916.044.505.966.536.346.124.495.684.915.00
Basic earnings per share / ADR (DKK)
4.7410.936.064.505.966.546.346.134.505.704.925.02
Adjusted diluted earnings per share / ADR (Non-IFRS, DKK)
6.186.636.446.566.366.826.856.235.785.92
Average diluted shares outstanding (millions)(M)
4,4364,4494,4494,4474,4474,4464,4564,4614,4654,4714,4774,489
Free cash flow (Non-IFRS, DKKm)2
42,524.0012,773.00-35,592.0030,316.0027,113.0011,308.00-86,467.0030,451.0036,289.005,020.00-7,250.0030,039.00
Net cash generated from operating activities (DKKm)
55,199.0024,084.007,619.0046,107.0041,774.0024,730.0012,301.0043,850.0050,503.0014,314.009,551.0040,966.00
Capital expenditure — purchase of property, plant and equipment (DKKm)
12,675.0011,311.0018,429.0013,628.0014,661.0013,422.0016,101.0012,119.0010,470.008,474.009,407.005,828.00
Net debt (negative = net debt position, DKKm)4
-86,523.00-115,919.00-95,424.00-59,898.00-73,268.00-70,147.00-69,713.0023,816.0011,658.00-11,954.00
Equity ratio (Total equity as % of total assets, %)(%)
37.2%36.3%35.7%33.2%34.9%28.3%30.8%30.3%30.5%33.1%33.9%31.0%
Cash at bank (quarterly balance sheet, DKKm)
44,482.0021,127.0026,464.0032,084.0018,435.0038,938.0015,655.0057,018.0052,821.006,324.0014,392.0030,144.00
Marketable securities (quarterly balance sheet, DKKm)
500.00499.00498.00499.00499.002,612.0010,653.0017,863.009,833.002,979.0015,838.0017,451.00
Current borrowings (quarterly balance sheet, DKKm)
18,333.0027,210.0012,017.0012,034.0011,963.0022,413.0013,113.005,520.005,452.0010,164.006,478.006,613.00
Full-time equivalent (FTE) employees — end of period
68,794.0068,794.0078,387.0077,406.0076,302.0071,880.0069,260.0066,015.0063,370.0061,412.00
Danish Krone to U.S. Dollar spot exchange rate (DKK per 1 USD, FRED EXDNUS)
6.436.386.426.396.587.097.006.796.936.876.936.85
U.S. Personal Consumption Expenditures: Health Care — SAAR ($B)(M)
3,7903,7003,6673,6153,5303,4653,4183,3583,2883,2443,1593,079
Net sales / Revenue (DKKm)15
78,488.0096,823.0079,144.0074,976.0076,857.0078,087.0085,683.0071,311.0068,060.0065,349.0065,863.0058,731.00
Cost of goods sold (DKKm)
17,100.0013,598.0012,846.0012,890.0011,308.0010,274.009,916.009,713.00
Gross profit (DKKm)
61,388.0083,225.0063,996.0057,072.0064,011.0065,197.0072,659.0060,003.0057,786.0055,433.0055,849.0049,018.00
Research and development costs (DKKm)
17,787.0010,284.0014,648.0015,393.0011,690.0010,308.0013,802.009,488.0016,166.008,606.0010,460.008,128.00
General and administrative costs (DKKm)
1,309.001,140.001,549.001,884.001,316.001,220.001,580.001,382.001,157.001,157.001,456.001,256.00
Operating profit / EBIT (DKKm)
27,061.0059,618.0031,736.0023,682.0033,449.0038,791.0036,737.0033,822.0025,934.0031,846.0026,766.0026,913.00
EBITDA (DKKm)
37,365.0063,154.0037,298.0031,439.0038,282.0042,621.0041,935.0035,972.0034,779.0034,760.0029,758.0029,438.00
Financial / Interest income (DKKm)
1,314.006,053.00614.00307.005,314.003,425.003,913.00-821.00960.002,146.00-944.003,318.00
Financial / Interest expense (DKKm)
-1,500.00-3,499.001,835.001,528.00-4,958.00-5,183.00-5,093.001,383.00-1,562.00-2,074.001,798.00-2,168.00
Profit before income taxes (DKKm)
26,875.0062,172.0034,185.0025,517.0033,805.0037,033.0035,557.0034,384.0025,332.0031,918.0027,620.0028,063.00
Income taxes (DKKm)
5,886.0013,615.007,294.005,511.007,302.007,999.007,327.007,083.005,282.006,511.005,657.005,585.00
Net profit (DKKm)
20,989.0048,557.0026,891.0020,006.0026,503.0029,034.0028,230.0027,301.0020,050.0025,407.0021,963.0022,478.00
Basic earnings per share (DKK)
4.7410.936.064.505.966.546.346.134.505.704.925.02
Diluted earnings per share (DKK)
4.7510.916.044.505.966.536.346.124.495.684.915.00
Weighted-average basic shares outstanding (millions)(M)
4,4444,4444,4434,4404,4464,4524,4584,4604,4654,477
Weighted-average diluted shares outstanding (millions)(M)
4,4364,4494,4494,4474,4474,4464,4564,4614,4654,4714,4774,489
Total assets (DKKm)5
594,941.00559,221.00542,902.00512,288.00482,153.00489,162.00465,630.00397,441.00369,383.00298,921.00314,486.00300,101.00
Total current assets (DKKm)3
208,696.00177,317.00172,453.00181,883.00162,705.00174,395.00161,788.00195,160.00177,500.00116,421.00139,646.00142,199.00
Cash and cash equivalents (DKKm)
44,482.0021,127.0026,464.0032,084.0018,435.0038,938.0015,655.0057,018.0052,821.006,324.0014,392.0030,144.00
Trade accounts receivable (DKKm)
88,949.0082,565.0070,856.0075,421.0069,575.0069,459.0071,949.0066,299.0063,565.0056,999.0064,770.0052,602.00
Inventories (DKKm)
51,352.0051,352.0049,623.0047,504.0045,652.0042,853.0040,849.0037,944.0036,356.0033,600.0031,811.0029,534.00
Property, plant and equipment, net (DKKm)
231,758.00219,974.00208,378.00193,244.00180,758.00172,376.00161,680.00119,832.00109,980.0098,230.0090,961.0081,461.00
Intangible assets, net (DKKm)
102,167.00110,033.00110,208.00106,587.00107,866.00109,379.0090,804.0054,488.0055,501.0059,640.0060,406.0055,726.00
Total liabilities (DKKm)3
373,664.00356,156.00348,855.00342,392.00314,087.00350,622.00322,144.00276,919.00256,861.00200,010.00207,925.00207,110.00
Total current liabilities (DKKm)
239,083.00225,158.00215,661.00234,358.00207,522.00236,117.00217,614.00208,358.00187,909.00165,606.00169,655.00172,552.00
Current borrowings / Short-term debt (DKKm)
18,333.0027,210.0012,017.0012,034.0011,963.0022,413.0013,113.005,520.005,452.0010,164.006,478.006,613.00
Trade payables (DKKm)
14,591.0014,803.0019,758.0023,904.0028,206.0019,576.0017,140.0024,079.0029,759.0013,006.0025,606.0020,106.00
Total equity (DKKm)1
221,277.00203,065.00194,047.00169,896.00168,066.00138,540.00143,486.00120,522.00112,522.0098,911.00106,561.0092,991.00
Retained earnings (DKKm)
224,164.00206,420.00195,298.00168,529.00164,453.00137,319.00144,448.00121,670.00112,150.0099,050.00104,839.0091,735.00
Operating cash flow (DKKm)2
55,199.0024,084.007,619.0046,107.0041,774.0024,730.0012,301.0043,850.0050,503.0014,314.009,551.0040,966.00
Capital expenditure (DKKm)
12,675.0011,311.0018,429.0013,628.0014,661.0013,422.0016,101.0012,119.0010,470.008,474.009,407.005,828.00
Free cash flow (DKKm)
42,524.0012,773.00-35,592.0030,316.0027,113.0011,308.00-86,467.0030,451.0036,289.005,020.00-7,250.0030,039.00
Geographic Segment Revenue — U.S. Operations (DKKm)5
40,869.0062,145.0044,743.0041,144.0042,963.0044,316.0052,372.0039,844.0038,404.0036,782.0040,067.0032,936.00
Geographic Segment Revenue — International Operations (DKKm)
37,619.0034,678.0034,401.0033,832.0033,894.0033,771.0030,319.0028,713.0027,130.0026,069.0023,242.0023,683.00
Geographic Segment Revenue — EUCAN (DKKm)
19,206.0017,918.0018,112.0016,767.0016,447.0014,765.00
Geographic Segment Revenue — Emerging Markets (DKKm)
8,413.006,861.007,467.006,635.007,544.008,790.00
Geographic Segment Revenue — APAC (DKKm)
5,030.005,125.005,038.005,466.005,615.004,594.00
Geographic Segment Revenue — Region China (DKKm)
4,970.004,774.003,784.004,964.004,288.005,622.004,324.004,708.004,963.004,506.003,418.004,341.00

12 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Reporting currency & fiscal calendar: Novo Nordisk A/S reports under IFRS in Danish kroner (DKK; standard table unit is million DKK / DKKm) on a calendar fiscal year ending December 31 (latest completed fiscal year: FY2025 ended December 31, 2025; latest completed quarter: Q2 2026 ended June 30, 2026; latest monthly share repurchase & FX data: October 2026).
  • Groups 1–3 provide the complete quarterly (Q1 2018–Q2 2026, 34 consecutive quarters) and annual (FY2015–FY2025) Brand × Geography Sales Matrix and Constant Exchange Rate (CER) growth rates across Obesity Care (Wegovy® injectable, Wegovy® pill launched Q1 2026 in the U.S., and Saxenda®), GLP-1 Diabetes (Ozempic®, Victoza®, and Rybelsus® / Ozempic® pill), Insulins (Long-acting: Tresiba®, Xultophy®, Levemir®, Awiqli®; Premix: Ryzodeg®, NovoMix®; Fast-acting: NovoRapid®, Fiasp®; Human insulin), and Rare Disease (Rare blood disorders: NovoSeven®, Haemophilia A & B; Rare endocrine disorders: Norditropin®, Sogroya®), including the Q1–Q2 2026 reconciliation between IFRS Reported Sales, the DKK 26,760m U.S. 340B Drug Pricing Program rebate provision reversal, and Adjusted Sales.
  • Groups 4–6 cover U.S. Gross-to-Net (GTN) Sales Deductions by payer channel (73.0% of U.S. gross sales in FY2025: DKK 247,003m Managed Care & Medicare Part D rebates, DKK 178,735m wholesaler charge-backs & 340B discounts, DKK 56,574m Medicaid rebates) and the Balance Sheet rebate provision rollforward (DKK 121,499m liability at FY2025), IQVIA global market shares (FY2018–FY2025), quarterly & annual Patient Reach (46.5m total patients reached in Q2 2026, including 4.9m in Obesity care, 41.6m in Diabetes care, 6.6m vulnerable patients, and 90,432 children in Changing Diabetes® in Children), standalone quarterly Scope 1/2/3 GHG emissions & Plastic Footprint (0.35 kg/patient in Q2 2026), R&D expenses by nature, and DKK 177,031m of off-balance-sheet contractual commitments (including DKK 91,031m CMO obligations and DKK 130,622m PP&E Construction in Progress).
  • Groups 7–11 cover Quarterly Condensed Financial Statements, Non-IFRS reconciliations (EBITDA, Free Cash Flow, Net Debt, ROIC of 39.3% in FY2025), Monthly Safe Harbour Share Repurchase Programme execution through October 2026 (40.27m B shares repurchased for DKK 11,187.3m at DKK 277.78/share since Feb 2026; 54.31m treasury shares = 1.2% of share capital), Workforce & Executive Remuneration, Form 11-K Audited U.S. ($2,880.1M) & Puerto Rico ($7.99M) 401(k) Savings Plans, Parent Company Novo Nordisk A/S standalone financial statements (DKK 289,015m net sales, DKK 100,382m net profit, DKK 480,795m assets), FRED FX & U.S. Pharma Macro Benchmarks, and Postgres Database reference series.

Không hiện vì thiếu các kỳ gần đây (3)

  • Quarterly IQVIA Diabetes, GLP-1 & Obesity Market Share Percentages in Q1–Q2 2026 — Reported quarterly in Form 6-K through Q4 2025 under the 'Strategic Aspirations 2025' framework, but discontinued in the Q1 2026 and Q2 2026 Form 6-K announcements; retained as continuous annual series (FY2018–FY2025).
  • Compoundbound / Qualitative Pipeline & Supply Chain Disclosures — Approximate or bound statements such as 'more than 1,800 employees in LTI programme', 'sales in Russia and Ukraine constituted less than 1% of global sales', and 'around 55% volume share' are excluded from table cells per Step 5 rules.
  • Consolidated minus Parent Company (Novo Nordisk A/S) Subtraction — Parent Company Novo Nordisk A/S reports under the Danish Financial Statements Act (Class D) and records DKK 289,015m of standalone net sales (93.5% of consolidated sales) including intra-group sales of bulk/finished drugs to global distribution affiliates; therefore Parent Company statements are presented directly as reported in Group 9 without subtraction.

Dữ liệu cập nhật 2026-11-03.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Obesity Care & GLP-1 Diabetes Franchise (Brand × Geography Matrix & CER Growth)

Insulin Portfolio & Total Diabetes Care (Brand × Geography Matrix & CER Growth)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Novo Nordisk A S

See a number that looks wrong?